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ABSTRACT 
 
 
Introduction: Stockpiling of unused medications by community-dwelling 
individuals results in Community-Based ACcumulation of Home mEdicationS 
(CACHES).  CACHES place the individual, health care and justice system, and 
ecosystem at risk for adverse outcomes including: a) diversion of prescription 
medications by friends and family, b) pediatric poisonings, c) adverse drug events, d) 
increased criminal justice system costs related to prescription drug abuse, e) increased 
health care costs, and f) pollution of local water supplies via improper medication 
disposal.  This study explores the relationship among individual risk factors (gender, 
race, age, comorbid conditions), geographical location, health care risk factors (number 
of prescribers and dispensaries), and CACHES.  
 
Methods: This study involved an analysis of existing data extracted from death 
scene charts created by the Medical Examiners and Medicolegal Death Scene 
Investigators of Forensic Medical, PLC in Nashville, Tennessee from January 1 through 
December 31, 2011.  The study examined the prevalence, size, and composition of 
CACHES found in decedents’ homes.  In addition, this study included a descriptive 
analysis of demographic data (gender, race, age, and comorbid conditions) and presence 
of CACHES.  Additionally, the geographic locations of CACHES were identified.  
Finally, the relationship between health care risk factors (number of prescribers and 
dispensaries) and CACHES was explored.   
 
Results: The analyses showed no statistical differences in gender, race, or age 
between decedents with medications (used and unused) in the home and decedents 
without medications.  The study sample was predominantly male, Caucasian/Non-
Hispanic, and older than the Davidson County population.  Fifty-six percent of decedents 
had CACHES.  More than half had ≥ 4 bottles of unused medications with a mean of 38.9 
± 43.7 pills.  Sixty percent of the unused medications came from two major classes – 
those affecting the central nervous system and the cardiovascular system.  The CACHES 
group was significantly older, had a higher likelihood of having a psychiatric diagnosis, 
and used more prescribers and dispensaries.  The analyses did not support a statistical 
difference between the two groups with regards to gender, race, or total number of 
comorbid conditions.  There was insufficient data to perform an analyses on the 
relationship between geographical location (Zip code) and CACHES.   
 
Discussion/Conclusions: Limitations in the original data as well as differences in 
study design complicated a direct comparison of the prevalence, size, and composition of 
the CACHES to other studies.  However, this exploratory study corroborates the 
CACHES model’s assertion that the stockpiling of unused medications is a pervasive 
problem.  Furthermore, the analyses support advanced age, having a psychiatric comorbid 
condition, and the use of multiple prescribers and dispensaries increases the individual’s 
risk for the accumulation of unused medications in the home.  Additional research is 
needed to further illuminate the relationship between gender, race, and the number of 
comorbid conditions and CACHES. 
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CHAPTER 1.    INTRODUCTION 
 
 
Overview 
 
Stockpiling of unused prescription and over-the-counter medications by health 
care consumers results in Community-Based ACcumulation of Home mEdicationS 
(CACHES).  CACHES endanger public health placing the individual, health care and 
justice systems, and the ecosystem at risk for adverse outcomes.  Adverse outcomes 
include: a) youth and adults diverting prescription medications from the family medicine 
cabinet for the purpose of getting high; b) pediatric poisonings secondary to accidental 
ingestion of prescription or over-the-counter medications; c) increased emergency 
department visits and hospitalizations related to adverse drug events (ADEs); d) 
increased criminal justice system costs related to prescription drug abuse (e.g. theft, 
victimization costs, incarceration); e) increased health care costs associated with the 
treatment of prescription drug overdose, misuse, and abuse; and f) pollution of local 
water supplies because of improper disposal of unused medications via sewering - 
defined as flushing medications down the sink or toilet.  
  
Researchers Christian Daughton and Ilene Ruhoy developed several theoretical 
models addressing the issue of accumulated medications, improper disposal, and the 
entry points of Active Pharmaceutical Ingredients (APIs) into the environment.  Each of 
these models have a different focus including: a) the mechanisms by which the individual 
consumer stockpiles medication and introduces APIs into the environment (Ruhoy & 
Daughton, 2007); b) the accumulation of unused medications in places such as hospitals, 
long term care facilities, veterinary offices, livestock farms, and pharmaceutical factories 
and their preferred disposal routes (Ruhoy & Daughton, 2008); c) factors affecting health 
care providers prescribing habits their contribution to medication wastage (Ruhoy & 
Daughton, 2008); d) the pathways of biologic exposure to APIs for both humans and the 
environment (Daughton & Ruhoy, 2008); and e) how “one-size-fits-all” prescribing 
behaviors and nonadherence contribute to medication stockpiling and subsequent adverse 
outcomes including increased healthcare costs, poisonings, and diversion (Daughton & 
Ruhoy, 2013). 
 
The CACHES model builds upon these existing models while incorporating 
additional supporting literature.  In addition, the CACHES model offers perspective on 
external (federal and state regulations, health care system) and individual factors leading 
to the development of CACHES and the adverse outcomes associated with stockpiled 
medications in the home. 
 
 
Purpose of the Study 
 
The purpose of this pilot study was to examine the prevalence, size, and 
composition of CACHES found in decedents’ homes in Davidson County, Tennessee 
from January 1, 2011 through December 31, 2011.  In addition, this study sought to 
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investigate the individual, geographic, and health care risk factors associated with the 
formation of CACHES.  Individual risk factors included gender, race, age, and comorbid 
conditions.  Geographic risk was examined through capturing the location of CACHES 
data by Zip code.  Finally, health care risk factors included the number of prescribers and 
number of dispensers associated with CACHES.  
 
 
Specific Aims 
 
 The CACHES pilot study had five specific aims including: 
 
 
Specific Aim One 
 
To describe the prevalence of CACHES found in decedents’ homes in Davidson 
County, Tennessee from January 1, 2011 through December 31, 2011. 
 
 
Specific Aim Two 
 
To examine the size and composition of CACHES found in decedents’ homes in 
Davidson County, Tennessee from January 1, 2011 – December 31, 2011. 
 
 
Specific Aim Three 
 
 Among decedents with medications in the home, to compare individual risk 
factors (gender, race, age, comorbid conditions) between those with CACHES and those 
without CACHES. 
 
 
Specific Aim Four 
 
 To describe the relationship between geographic location (Zip code) and the 
presence of CACHES in decedents’ homes. 
 
 
Specific Aim Five 
 
 Among decedents with medications in the home, to compare health care systems 
risk factors (number of prescribers, number of dispensaries) between those with 
CACHES to those without CACHES. 
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Significance 
 
Over the last two decades, there has been an increase in prescription and over the 
counter (OTC) drug use across all age groups in the United States (Gu, Dillon, & Burt, 
2010; Kaiser Family Foundation, 2010a; Raofi & Schappert, 2006; Thomas, Conrad, 
Casler, & Goodman, 2006).  In 2011, Tennessee had the third highest rate of 
prescriptions per capita at 17.6 with the national average being 12.1 (Kaiser Family 
Foundation, 2011b).  There has been a corresponding increase in the misuse and/or abuse 
of certain prescription drug classes especially opioids, benzodiazepines, and stimulants 
(U.S. Drug Enforcement Administration, 2012).  The 2010 National Survey on Drug Use 
and Health (NSDUH) results show 7.0 million persons ≥ 12 years of age reporting the 
nonmedical use of prescription drugs in the past month including using these drugs to get 
high (Substance Abuse and Mental Health Services Administration, 2011c).  The 
majority (70%) of first-time misusers accessed these prescription drugs from the family 
medicine cabinet, a family member, or friend (Office of National Drug Control Policy, 
2011; Substance Abuse and Mental Health Services Administration, 2011c).  
 
Unused medications also pose a household hazard to young children (Bronstein et 
al., 2011; Bronstein et al., 2010; Meyer et al., 2007; Schillie, Shehab, Thomas, & 
Budnitz, 2009; Substance Abuse and Mental Health Services Administration, 2010a).  An 
analysis of data from the National Electronic Injury Surveillance System collected during 
2004 through 2005 identified approximately 58,000 Emergency Department (ED) visits 
made by children for treatment of accidental poisonings secondary to the consumption of 
over-the-counter (OTC) or prescription medications (Schillie et al., 2009).  Reflecting the 
upward trend of prescription drug use, a follow up study in 2008 identified 69,121 ED 
visits related to accidental ingestion of pharmaceuticals by children ≤ 5 years of age 
(Substance Abuse and Mental Health Services Administration, 2010a). 
 
 Stockpiles of unused and expired medications can lead to the individual being 
confused as to which medications are current versus those that have been discontinued.  
This situation contributes to accidental ingestion of duplicate classes of medications, 
overdosing, increased likelihood of drug-drug interactions, and/or the use of 
contraindicated medications.  These medication errors contribute to adverse drug events 
(ADEs).  Older adults are the most frequent consumers of prescription medications.  As 
such they are at particular risk for these types of medication errors and subsequent 
adverse drug events, which often require a trip to the ED or hospitalization (Green, 
Hawley, & Rask, 2007; Prybys, Melville, Hanna, Gee, & Chyka, 2002; Wasserfallen, 
Bourgeois, Bula, Yersin, & Buclin, 2003; Werder & Preskorn, 2003).  
 
 Federal and state regulatory barriers limit consumer access to safe and efficient 
disposal choices for unused and/or expired medications.  As a result, in addition to 
stockpiling unused medications, individuals frequently improperly dispose of 
medications in the trash or via flushing down the sink or toilet (Abrons, Vadala, Miller, & 
Cerulli, 2010; Glassmeyer et al., 2009; Kotchen, Kallaos, Wheeler, Wong, & Zahller, 
2009; Kuspis & Krenzelok, 1996; Ruhoy & Daughton, 2008; Seehusen & Edwards, 
2006; Wennmalm, Gunnarsson, & Eckermann, 2010).  Components of these medications, 
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termed Active Pharmaceutical Ingredients (APIs), eventually end up in local streams and 
rivers, as well as drinking-water supplies (Barnes et al., 2008; Daughton & Ruhoy, 
2009a; Daughton, 2010b; Glassmeyer et al., 2009; Stackelberg et al., 2004; Wennmalm et 
al., 2010; Westerhoff, Yoon, Snyder, & Wert, 2005).  APIs have a negative impact on the 
health of aquatic (Bound & Voulvoulis, 2005; Gross-Sorokin, Roast, & Brighty, 2006; 
Jobling, Nolan, Tyler, Brighty, & Sumpter, 1998; Kidd et al., 2007; Orlando et al., 2004), 
microbe (Furtula et al., 2010; Schwartz, Kohnen, Jansen, & Obst, 2006; Wennmalm et 
al., 2010; Zhang, Zhang, & Fang, 2009), and higher level life forms (Oaks et al., 2006; 
Roig, Greenwood, & Barcelo, 2009). 
 
A two-month doctoral internship with the Office of National Drug Control Policy 
(ONDCP) afforded insight into the Obama Administration’s current policies regarding 
public health risks associated with medications in the home, the potential for misuse, 
abuse, and diversion, and the Administrations’ public policy recommendations to effect 
change.  This internship provided networking opportunities with federal and state-level 
professionals involved in addressing prescription drug misuse and abuse.  In addition, 
meetings including the ONDCP, Food and Drug Administration (FDA), Department of 
Justice (DOJ), Drug Enforcement Administration (DEA), the Substance Abuse and 
Mental Health Services Administration (SAMHSA), the American Medical Association 
(AMA), and state leaders in health care focused on the contributory role of federal and 
state regulations in the development of CACHES and the associated adverse outcomes 
for the individual, health care, and criminal justice system (Office of National Drug 
Control Policy, 2008, 2011).  These observations and insights are incorporated into the 
CACHES conceptual framework. 
 
 
Assumptions 
 
The assumptions made during the development of the conceptual framework, 
methods, and analyses include:   
 
1. Medicolegal Death Investigators (MLDIs) and Medical Examiners Board 
Certified Forensic Pathologists (MEBCFPs) follow the National Association 
of Medical Examiners (NAME) guidelines and Tennessee legal code 
regarding the collection and reporting of death scene data including: 
medications, on-scene investigation notes and photography, autopsy and 
toxicology reports, and the recording of Death Certificate data including the 
cause, nature, and contributing factors of death. 
 
2. Prescription and OTC medications in the home serve as a public health threat 
to the individuals living or visiting in the home. 
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Limitations 
 
This study included the following limitations: 
 
1. The data were obtained via a convenience sampling of decedents examined by 
Forensic Medical, PLC. Forensic Medical is called onto a death scene of a 
violent (homicide), traumatic (suicide, accidental), or unexpected death.  
These data may not be representative of the larger population. 
 
2. The data were restricted to in-home deaths in Davidson County, Tennessee.  
These data may not be representative of populations in other geographical 
regions.  
 
3. According to Tennessee law, MLDIs may only search for and collect 
medications that are: a) stored in “typical” locations such as the family 
medicine cabinet, bathroom and kitchen counters, refrigerator, and/or bedside 
table; or, b) in “plain sight”; and, c) are prescribed and dispensed to the 
decedent.  As a result of these medicolegal processes, it is likely the study data 
are an underrepresentation of the number of medications stockpiled in the 
decedents’ homes.   
 
4. The pilot study sample size does not provide sufficient power for correlational 
statistics.  As a result, the findings are limited to a descriptive analysis of the 
data.   
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CHAPTER 2.    LITERATURE REVIEW AND CONCEPTUAL FRAMEWORK 
 
 
The purpose of this chapter is to: a) document search strategies in the review of 
the CACHES literature, b) describe expanded search strategies, c) examine and critique 
existing models, d) identify the gaps in the CACHES literature, e) explicate the CACHES 
model’s concepts and propositions, and f) describe how the CACHES model provides a 
foundation for future research and practice. 
 
 
Search Strategies 
 
The first step in the development of the CACHES conceptual model was to 
evaluate the current literature.  A search of the literature, using PubMed, OVID, and 
Google Scholar, highlighted an interdisciplinary interest in CACHES with germane 
articles found in nursing, medical, pharmacy, environmental chemistry, microbiology, 
and environmental health journals.  Search limits consisted of English language articles 
published from 1980 to present.  Key search terms included: adverse drug events, 
poisonings, drug disposal, hoarding and sharing medications, age, race, gender and health 
care utilization, pharmaceutical waste, prescription drug abuse and misuse, and diversion. 
 
 
Seminal Articles 
 
The initial review of the literature identified a handful of seminal articles co-
authored by Drs. Christian Daughton and Ilene Ruhoy.  These two researchers developed 
several conceptual models including: a) Disposal as a Contributor to Drugs in the 
Environment (Ruhoy & Daughton, 2007), b) Accumulation and  Disposal of 
Pharmaceuticals (Ruhoy & Daughton, 2008), c) Unanticipated Exposure to Active 
Pharmaceutical Ingredient (APIs) Residue from the Environment (Daughton & Ruhoy, 
2008), d) Factors Influencing Drug Consumption (Ruhoy & Daughton, 2008), and e) 
One-Size-Fits-All Drug Dosing: Risks to Health and the Environment, and Increased 
Health Care Costs (Daughton & Ruhoy, 2013).  These conceptual frameworks are 
discussed in more detail under the existing models section.  Written communication with 
Dr. Daughton resulted in access to a 10,000-citation database of primarily environmental 
references housed on the United States Environmental Protection Agency’s (EPA) 
website.  In addition, a phone conference with a regional EPA representative, Virginia 
Thompson (Philadelphia Office), provided additional feedback on the development of the 
CACHES conceptual framework. 
 
 
Expanded Search Strategies 
 
The standard search engines (PubMed, Google Scholar, and OVID) provided 
access to relevant peer-reviewed literature.  However, these peer-reviewed articles 
provided minimal national, regional, and state statistics on prescription drug misuse, 
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abuse, and diversion, poisonings, overdoses, and prescription drug-related crime data.  In 
addition, the scientific literature did not offer sufficient commentary on the role of federal 
and state regulations on medication disposal laws.  These gaps in the scientific literature 
required the use of expanded search strategies as indicated in Table 2-1. 
 
 
Existing Models 
 
Ruhoy and Daughton developed five major conceptual models addressing the 
issue of medication accumulation, disposal practices, and the introduction of APIs into 
the ecosystem.  What follows is an examination of these models, identification of existing 
gaps, and an introduction to the CACHES model. 
 
 
Ruhoy and Daughton 2007 
 
 In their 2007 article, Ruhoy and Daughton presented their conceptual framework, 
“Disposal as a Contributor to Drugs in the Environment”.  In this model, they identify the 
mechanisms by which the individual consumer introduces APIs into the environment.  
These mechanisms include: a) excretion of APIs by humans into sewer systems, b) 
sewering of topical APIs secondary to bathing, c) introduction of “leftover” medications 
into landfills via household trash, and d) purposeful sewering of unused medications via 
flushing down the sink or toilet (Ruhoy & Daughton, 2007).  Ruhoy and Daughton 
(2007) identify one outlier disposal method, “Take-Backs”, which result in the 
incineration of unused consumer medications.  In their model, this particular disposal 
method does not contribute to the introduction of APIs into the environment.  Ruhoy and 
Daughton (2007) also highlight how leftover medications can accumulate in the 
consumer’s home through behaviors such as inadvertent and/or purposeful stockpiling.  
They propose a portion of these stockpiled medications are diverted from the consumer’s 
household for purposeful abuse or can contribute to pediatric accidental poisonings 
(Ruhoy & Daughton, 2007). 
 
 
Ruhoy and Daughton 2008 
 
 In their second conceptual model, “Accumulation and Disposal of 
Pharmaceuticals”, Ruhoy and Daughton (2008) enlarge the scope of their previous model 
from the individual as the primary medication accumulation point to also include: 
physician outpatient clinics, pharmacies at long term care facilities and hospitals, 
outpatient pharmacies, hospices, veterinary offices, agriculture centers, and reverse 
distributors.  In addition, this model identifies the mechanisms of disposal used at each of 
these accumulation points as either sewering, landfills, or incineration (Ruhoy & 
Daughton, 2008). 
 
“Factors Influencing Drug Consumption” identifies the factors influencing health 
care providers’ prescribing habits and the dispensing of medications.  In addition, the  
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Table 2-1. Expanded Sources Searched for the Review of Literature 
 
Topics Sources 
National, regional, and state statistics 
on prescription drug misuse, abuse, 
and diversion 
National Drug Intelligence Center  
Office of National Drug Control Policy 
Substance Abuse and Mental Health 
  Services Administration 
 
National trends in accidental pediatric 
prescription drug poisonings 
Substance Abuse and Mental Health 
  Administration  
 
Morbidity and mortality data related 
to adverse drug events, misuse, abuse, 
and overdoses on prescription drugs 
Center for Disease Control and Prevention 
Substance Abuse and Mental Health 
  Services Administration 
Department of Transportation  
 
Crime rates related to prescription 
drug misuse/abuse 
 
National Drug Intelligence Center  
 
Current federal policy statements 
regarding prescription drug epidemic 
Drug Enforcement Administration 
Office of National Drug Control Policy 
Substance Abuse and Mental Health 
  Services Administration 
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researchers list specific patient behaviors (increased consumer acquisition, nonadherence) 
leading to increased accumulation of consumer medication wastage (Ruhoy & Daughton, 
2008).  This model also suggests potential changes by both providers (small quantity 
trials, installment dispensing, abuse and addiction prevention, medication reuse) and 
patients (concordance) to reduce this wastage (Ruhoy & Daughton, 2008). 
 
 
Daughton and Ruhoy 2008 
 
The conceptual model, “Unanticipated Exposure to Active Pharmaceutical 
Ingredient (APIs) Residue from the Environment” highlights the pathways of biologic 
exposure for both humans and the environment to APIs (Daughton & Ruhoy, 2008).  The 
authors emphasize this exposure is done without consent and the source of these 
exposures stems from the introduction of APIs to sewage via excretion and disposal of 
medications (Daughton & Ruhoy, 2008). 
 
 
Daughton and Ruhoy 2013 
 
“One-Size-Fits-All Drug Dosing: Risks to Health and the Environment, and 
Increased Health Care Costs” identifies prescribing behaviors (dose larger than needed to 
achieve therapeutic outcome, polypharmacy) and patient factors (adverse drug reactions, 
self-medicating, noncompliance) responsible for the accumulation of excess medications.  
In addition, this model focuses on the downstream impact of these excesses, including: 
introduction of APIs into the environment, increased health care costs, poisonings, 
diversion, and abuse (Daughton & Ruhoy, 2013). 
 
 
Gaps in the Models 
 
While there is growing evidence of concern about CACHES, there are limitations 
in the existing conceptual models as well as gaps in the literature as to the contributing 
factors and adverse outcomes associated with CACHES.  Ruhoy’s and Daughton’s 
models provide an in depth analysis of where unused medications accumulate at the 
micro (consumer) and macrosystem (health care, agricultural, and pharmaceutical 
industry) level and how these systems dispose of these unwanted medications.  
 
 In addition to Ruhoy and Daughton’s work, there are a handful of other studies 
examining the stockpiling of unused and expired medications in the home setting.  
However, the majority of these studies were done in Europe, the Middle East, New 
Zealand, and Australia.  There has not been extensive research on this topic in the United 
States (U. S.).  It is difficult to generalize the findings of these studies to the U.S. when 
taking into consideration the differences in the health care systems (e.g. fewer 
prescriptions per capita, centralized health care system, pharmacy-as-disposal site) and 
possible demographic variations. 
 
 10 
CACHES Model 
 
The CACHES model (Figure 2-1) includes six major concepts: health care 
system (HCS), federal and state regulations, individual, CACHES, criminal justice 
system (CJS), and ecosystem.  In addition, the model identifies characteristics for each of 
the major concepts.  On the left-hand side, three major concepts (health care system, 
federal and state regulations, individual) and their characteristics are classified as risk 
factors leading to the stockpiling of medications in the home.  Multiple prescribers, 
multiple providers, and prescribing practices are health care system characteristics 
directly contributing to the individual’s risk for CACHES.  The Controlled Substance Act 
(1970) and pharmacy rules and regulations, characteristics of state and federal 
regulations, also increase the individual’s risk for accumulating unused medications in 
the home.  Finally, characteristics of the individual (gender, race, age, comorbid 
conditions, polypharmacy, nonadherence, drug costs, drug hoarding, drug sharing, 
perceptions of medication safety, and geographic location) affect the individual’s risk for 
having CACHES in the home setting.  
 
 Adverse outcomes associated with CACHES are indicated on the right-hand side 
of Figure 2-1.  For the individual, adverse outcomes include: poisonings, misuse or abuse 
of prescription medications, and adverse drug events.  Increased utilization of health care 
resources and unused medications representing wasted health care dollars are health care 
system associated adverse outcomes.  Adverse outcomes in the criminal justice system 
include victimization costs and increased drug-related arrests and incarcerations.  
Inappropriate disposal of CACHES of prescription drugs introduce active pharmaceutical 
ingredients (APIs) into sewers and landfills, ultimately adversely affecting the ecosystem.  
Finally, these APIs eventually contaminate local water supplies thereby placing the 
individual at risk for exposure.   
 
The concepts and their characteristics examined in this pilot study are highlighted 
in gray in Figure 2-1.  The individual characteristics include: gender, race, age, comorbid 
conditions, and geographic location.  Health care system characteristics are the number of 
prescribers and number of dispensaries.  Finally, data on the identified CACHES will be 
analyzed.  What follows is a definition for each major concept and their associated 
characteristics.  In addition, this section discusses the relationships between the major 
concepts, as well as the relationships between the associated characteristics and major 
concepts. 
 
 
CACHES Model: Risk Factors 
 
 
Health Care System 
 
 The health care system (HCS) is defined as the setting(s) in which the individual 
receives health care.  Examples of health care settings include: primary care office, 
specialty clinic, Emergency Department, hospital, substance abuse treatment center, and 
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Figure 2-1. Conceptual Framework for Community-Based ACcumulation of Home MEdicationS (CACHES) 
 
 12 
long term care facility.  As noted previously, the HCS plays a dual role in the CACHES 
model.  On the risk factors (left-hand) side of the model, the HCS has a positive 
contributory influence on the individual’s risk for CACHES.  In the United States (U.S.), 
health care delivery frequently is decentralized.  Health care consumers often are seen by 
multiple prescribers (primary care providers, specialists, dentists) and use multiple 
dispensaries (pharmacies).  Furthermore, provider prescribing practices contribute to the 
overprescribing of medications – in particular controlled substances.  In the CACHES 
model, both communication breakdowns among providers and provider prescribing 
practices place the individual at increased risk for CACHES. 
 
 
 Multiple prescribers.  In today’s health care system, patients often receive care 
in a variety of settings and from a variety of health care providers (Barat, Andreasen, & 
Damsgaard, 2000; Green et al., 2007; Prybys et al., 2002; Sorensen, Stokes, Purdie, 
Woodward, & Roberts, 2005, 2006).  The CACHES model defines these providers 
(physicians, nurse practitioners, physician assistants, and dentists) as prescribers – as 
each has the potential to write prescriptions for the individual seeking health care.  This 
decentralized health care delivery system is often complicated by a lack of 
communication among prescribers, which contributes to confusion as to what 
medications the patient is currently taking (Baena et al., 2006; Barat et al., 2000; Green et 
al., 2007; Junius-Walker, Theile, & Hummers-Pradier, 2006; Sorensen et al., 2005; 
Torrible & Hogan, 1997; Wasserfallen et al., 2003).  This confusion places the individual 
at risk for duplicate prescriptions (Sorensen et al., 2005, 2006; Torrible & Hogan, 1997), 
polypharmacy (Barat et al., 2000; Hajjar, Cafiero, & Hanlon, 2007; Junius-Walker et al., 
2006), and nonadherence (Baena et al., 2006; Barat et al., 2000; Sorensen et al., 2005).  
These issues not only place the individual at risk for adverse outcomes (Baena et al., 
2006; Barat et al., 2000; Gray-Winnett, Davis, Yokley, & Franks, 2010; Green et al., 
2007; Hajjar et al., 2007; Junius-Walker et al., 2006; Sorensen et al., 2005, 2006; Torrible 
& Hogan, 1997; Wasserfallen et al., 2003), but also contribute to the accumulation of 
unused and expired medications in the home (Barat et al., 2000; Daughton & Ruhoy, 
2008; Junius-Walker et al., 2006; Ruhoy & Daughton, 2008; Sorensen et al., 2005, 2006; 
Torrible & Hogan, 1997).  In the CACHES model, the use of multiple prescribers 
increases the individual’s risk for CACHES. 
 
 
Multiple dispensaries.  The CACHES model defines dispensaries as any 
commercial pharmacy (national chain pharmacies, independent pharmacies, physician 
clinics) where prescription and OTC medications are dispensed to the individual.  
Individuals obtaining prescriptions from multiple dispensaries are at higher risk for both 
duplicate prescriptions and contraindicated medication regimens (Boparai & Korc-
Grodzicki, 2011; Torrible & Hogan, 1997).  Duplicate prescriptions are defined as having 
two prescriptions for the same medication or within the same class of medications.  
Contraindicated medication regimens are defined as medications that, when taken 
concurrently, have a high risk for drug-drug interactions (Boparai & Korc-Grodzicki, 
2011; Torrible & Hogan, 1997).  Duplicative errors and the prescription of 
contraindicated medication regimens increased a patient’s risk for adverse drug events 
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(Boparai & Korc-Grodzicki, 2011; Torrible & Hogan, 1997).  The individual will often 
self-discontinue or is instructed by his/her provider to discontinue the medication(s) 
believed responsible for the adverse drug event (ADE).  In the setting of a 30- or 90-day 
supply of medications, this can result in a significant number of doses remaining unused.  
In disposal studies, patients report adverse drug events as a common reason for unused 
medications (Coma, Modamio, Lastra, Bouvy, & Marino, 2008; Langley, Marriott, 
Mackridge, & Daniszewski, 2005; Mackridge & Marriott, 2007; Shin, Kim, & Lee, 
2009).  Analysis of administrative drug claims data also identify the use of multiple 
dispensaries as a significant risk factor for the overprescribing, misuse and/or abuse of 
prescription opioids (Parente et al., 2004; Sullivan et al., 2010).  In the CACHES model, 
the use of multiple dispensaries places the individual at risk for the accumulation of 
unused medications in the home and adverse outcomes associated with these CACHES. 
 
 
 Prescribing practices.  Health care provider prescribing practices play a 
contributing role in the formation of CACHES.  Overprescribing of antibiotics, pain 
medications, and other classes of medications results in the accumulation of unused and 
expired medications in the home.  Of note, overprescribing is a term describing several 
different prescribing practices.  Overprescribing can be defined as writing a prescription 
when a pharmacological intervention is not required.  One common illustration of this 
practice is the prescribing of an antibiotic for a viral upper respiratory infection.  
Overprescribing also includes prolonged treatment duration for an acute health care issue.  
Multiple studies found this to be a common prescribing practice in the treatment of acute 
low back pain (Cantrill et al., 2012; Tacci, Webster, Hashemi, & Christiani, 1999).  In 
addition, prescribers often write “large prescriptions”, defined as a one to three month 
supply, (Steiner, Robbins, Roth, & Hammond, 1993) with the intent of increasing 
adherence via improved access to the medication (Steiner et al., 1993).  However, this 
practice can contribute to the accumulation of unused medications in the home when the 
medication is discontinued due to a lack of effectiveness, the patient has issues with side 
effects, and/or has a more serious adverse drug event (Steiner et al., 1993; Wennmalm et 
al., 2010).  The literature reflects a relationship between the above listed prescribing 
practices and unused medications.  Common reasons reported for the return of unused 
medications include a) physician discontinued medication (Langley et al., 2005; 
Mackridge & Marriott, 2007), b) adverse event (Langley et al., 2005; Mackridge & 
Marriott, 2007), and c) patient discontinued due to side effects (Langley et al., 2005; 
Mackridge & Marriott, 2007). 
 
At worst, the easy availability of certain classes of medications, specifically 
opioids, is identified as contributing to the increase of prescription drug misuse and 
abuse.  The majority of youth and adults reporting recent opioid misuse obtained these 
medications through a friend or family member (Substance Abuse and Mental Health 
Services Administration, 2011c).  Following the supply chain backwards, greater than 
70% of these friends and family members obtained their opioid prescription from one 
medical provider (Manchikanti & Singh, 2008; Substance Abuse and Mental Health 
Services Administration, 2011c).   
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 Over the last two decades, opioids have become the most commonly prescribed 
class of medications in the U.S. (Grady, Berkowitz, & Katz, 2011; Manchikanti & Singh, 
2008; Paulozzi & Xi, 2008; Volkow, McLellan, & Cotto, 2011).  A 2011 report analyzing 
pharmacy dispensing trends of generic and brand drugs showed hydrocodone ranked as 
the first and second most common prescription dispensed in the United States 
(Bartholow, 2012).  Nationwide, pharmacies dispensed 104,457,000 prescriptions for 
hydrocodone with the third most common prescription, Levothyroxine sodium, trailing 
far behind at 43,958,000 (Bartholow, 2012).  Wisniewski, Purdy and Blondell’s (2008) 
epidemiological study showed a statistically significant relationship between increased 
prescribing of opioids and the subsequent nonmedical use of opioid medicines.  This 
trend is associated with increased ED visits secondary to the sequelae related to 
prescription opioid misuse (Manchikanti et al., 2012; Wisniewski et al., 2008), as well as 
an increase in the number of deaths due to accidental overdoses of opioid medications 
(Manchikanti et al., 2012; Warner, Chen, & Makuc, 2009).   
 
 Health care providers report discomfort with prescribing opioids for the treatment 
of non-cancer pain (Bhamb et al., 2006; Breuer, Cruciani, & Portenoy, 2010; Paulozzi et 
al., 2012; Salinas et al., 2012; Wolfert, Gilson, Dahl, & Cleary, 2010).  Providers also 
report a gap in graduate education on best practices for prescribing prescription opioids 
(Breuer et al., 2010; Paulozzi et al., 2012; Wolfert et al., 2010).  As a result, many 
providers do not incorporate appropriate opioid abuse risk-reduction strategies including 
pain contracts, urine drug screens, short-scripts, or prescription drug monitoring 
programs (Bhamb et al., 2006; Paulozzi et al., 2012; Salinas et al., 2012; Wolfert et al., 
2010).  These prescriber behaviors contribute to increased access to and, subsequently, 
the misuse and/or abuse of prescription opioids in the United States (Paulozzi et al., 
2012). 
 
In response to these issues the Office of National Drug Control Policy, the 
Substance Abuse and Mental Health Administration, and the Food and Drug 
Administration, as well as several Congressional leaders, have proposed mandatory 
continuing education for health care providers who prescribe opioids (Food and Drug 
Administration, 2011a, 2011b; Paulozzi et al., 2012).  In November 2011, the FDA 
released for public comments a draft Risk Evaluation and Mitigation Strategy (REMS) 
for Schedule II, long-acting and extended-release opioids (Food and Drug 
Administration, 2011a).  Topics covered by the REMS include correct prescribing 
practices for Schedule II opioids; using the screening, brief intervention and referral to 
treatment (SBIRT) to identify patients with potential misuse/abuse issues; and  
incorporating prescription drug monitoring programs and pain contracts into the 
management of chronic pain patients (Food and Drug Administration, 2011a).   
 
In the CACHES model, provider prescribing behaviors have a direct effect on the 
individual – placing him/her at risk for CACHES of unused medications.  These 
behaviors include prescribing medications that are not warranted, prescribing long-scripts 
for an acute issue, and prescribing large prescriptions for a new medication without first 
establishing effectiveness or tolerance.  Furthermore, the overprescribing of prescription 
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opioids results in excess supplies in the home, which in turn is linked to the rising 
incidence of nonmedical use of prescription opioids. 
 
 
Federal and State Regulations 
 
Current federal and state regulations serve as barriers to the individual seeking 
safe and environmentally-friendly disposal of expired and unused medications.  In the 
CACHES model, federal and state regulations are defined as those laws and regulatory 
guidelines directly related to the disposal of unused prescription medications by the 
individual.  The Controlled Substance Act 1970 and Pharmacy rules and regulations are 
each discussed in turn. 
 
 
 Controlled Substance Act 1970.  The Comprehensive Drug Abuse Prevention 
and Control Act of 1970, also known as the Controlled Substance Act (CSA) dictates the 
manufacturing, distribution, prescribing, and dispensing of controlled substances 
("Comprehensive Drug Abuse Prevention and Control Act of 1970,," 1970).  Controlled 
substances are pharmaceuticals identified as having a high potential risk for abuse.  
Under the CSA, an end user is identified as the individual prescribed a controlled 
substance.  By law, the end user must dispose of unused controlled substances via 
sewering or throwing it in the trash.  In addition, he/she may return unused controlled 
substances to law enforcement officials such as local police departments, sheriff’s 
departments, drug enforcement administration officials, or specially designated “anti-
drug” National Guardsmen ("Comprehensive Drug Abuse Prevention and Control Act of 
1970,," 1970; Glassmeyer et al., 2009; Herring, Shah, Shah, & Gupta, 2008).   
 
The CSA law was designed specifically to reduce the diversion of legally 
prescribed controlled substances towards channels of illegal use/abuse.  Unfortunately, 
this law also serves as a barrier for easily accessible and environmentally-friendly 
disposal options for the individual with unused and unwanted controlled medications 
("Comprehensive Drug Abuse Prevention and Control Act of 1970,," 1970; Daughton, 
2003; Glassmeyer et al., 2009; Herring et al., 2008).  When surveyed, the majority of end 
users report flushing unused medications down the toilet or sink or throwing them out in 
the trash (Bound & Voulvoulis, 2005; Glassmeyer et al., 2009; Kallaos, Wheeler, Wong, 
& Zahller, 2007; Kuspis & Krenzelok, 1996; Seehusen & Edwards, 2006).  Many report 
lack of access to and/or discomfort with dropping off unused medications with law 
enforcement officials (Glassmeyer et al., 2009; Kallaos et al., 2007; Kotchen et al., 2009; 
Ortner & McCullagh, 2010).   
  
The CSA not only affects individual end users but also has a direct impact on 
hospices (McCullagh, Schim, & Ortner, 2012; Ortner & McCullagh, 2010), and in some 
instances, hospitals (Senft, 2010) and nursing homes (Senft, 2010).  Standard operating 
procedures for the disposal of controlled substances include sewering unused medications 
at the time of the patient’s death or discharge (Ortner & McCullagh, 2010).  This practice 
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was established with the goal of preventing staff or family members diverting the 
patient’s medications for nonmedical use (Ortner & McCullagh, 2010).   
 
 In October 2010, the U.S. Congress passed an amendment S. 3397 titled the “Safe 
and Secure Drug Disposal Act” significantly revising the Controlled Substance Act 
(CSA) of 1970.  Currently the DEA is holding public forums discussing how this 
amendment will affect regulatory standards (Jones, 2011).  The intent of this amendment 
is to open the door for pharmacies and community-based drug disposal efforts to receive 
unused controlled substances and other non-controlled prescription and over-the-counter 
medications for destruction without the need for direct law enforcement involvement 
(Glassmeyer et al., 2009; Jones, 2011; Office of National Drug Control Policy, 2011).   
 
 
 Pharmacy rules and regulations.  Variations in state pharmacy laws present a 
barrier to the enactment of Amendment S. 3397 (Center for Substance Abuse Research, 
2012; Daughton, 2003; Glassmeyer et al., 2009; Jones, 2011; Seehusen & Edwards, 
2006).  Local and state pharmacy boards and larger pharmacy groups, such as the 
National Association of Chain Drug Stores (NACDS), are opposed to becoming 
designated disposal sites (Seehusen & Edwards, 2006; Statement of the National 
Association of Chain Drug Stores on Drug Waste and Disposal, 2010).  They argue that 
the assumption of this role would result in increased risk for pharmacy theft, increased 
costs and the need for additional staff (Nola, 2011).  As currently written, there is no 
designated federal funding for pharmacy-based take back programs (Jones, 2011; Nola, 
2011).  The CACHES conceptual model identifies federal and state regulatory issues as 
logistical barriers for the individual interested in access to safe and environmentally-
friendly disposal options.  These barriers increase the risk of the accumulation of 
medications in the home. 
 
 
Individual 
 
In the CACHES model, the individual is defined as a community-dwelling 
person.  Of note, the individual plays a dual role in the CACHES model.  On the left-
hand side of the model (Figure 2-1), the individual has certain characteristics placing 
him/her at risk for stockpiling medications in the home.  These characteristics include a) 
gender, b) race, c) age, d) comorbid conditions, e) polypharmacy, f) nonadherence, g) 
drug coverage, h) drug hoarding, i) drug sharing, j) perceptions of medication safety, and 
k) geographic location.  Each characteristic is defined along with a discussion as to its 
effect on the individual’s risk for CACHES. 
 
 
 Gender.  In the CACHES model, gender is defined as male or female.  According 
to the literature, females are more likely than males to seek medical care; have higher 
health care expenditures, including prescription drug purchases; and use prescription 
drugs (Barat et al., 2000; Carrie, Grynmonpre, & Blandford, 2006; Fulton & Allen, 2005; 
Hofer-Ducklemann, 2012; Kaiser Family Foundation, 2010d; Linjakumpu et al., 2002; 
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Owens, 2008; Qato et al., 2008; Shin et al., 2009; Sorensen et al., 2005).  In the United 
States, the Kaiser Family Foundation National Survey (2010d) supports this difference 
with females filling 14.4 prescriptions/capita versus males who fill 9.5 
prescriptions/capita.  This gender gap is more pronounced when looking at the state-level 
data.  In Tennessee, females on average filled 21.0 prescriptions per year versus 14.1 for 
males in 2011 (Kaiser Family Foundation, 2011a).  Increased access and usage of 
prescription and OTC medications increases the likelihood of unused medications 
(Sorensen et al., 2005).  In the CACHES model, female gender increases the risk for the 
accumulation of unused and expired medications in the home (Sorensen et al., 2005).   
 
 
Race.  The CACHES model defines race according to the categories used by the 
state Medical Examiners in the completion of state-issued death certificates.  These 
categories include Caucasian/Non-Hispanic, African American, Hispanic, Asian, and 
Other.  Caucasian/Non-Hispanic patients are more likely to have access to and utilize 
health care resources when compared to Hispanic and African American patients (Adams 
et al., 2013; Gellad, Haas, & Safran, 2007; McClelland, Jorgensen, Post, Szklo, & 
Kronmal, 2013).  This trend can also be seen when looking at racial differences in 
prescription drug access (Adams et al., 2013; Gellad et al., 2007).  These findings are not 
surprising when comparing the rates of uninsured African Americans (21%) and 
Hispanics (32%) versus 13% of Caucasians (Kaiser Family Foundation, 2011c).   
 
Multiple studies have examined the relationship between race and medication 
nonadherence.  Findings indicate minority patients (African American and Hispanic) 
being less adherent than their Caucasian counterparts (Benner et al., 2002; Bosworth et 
al., 2008; Siegel, Lopez, & Meier, 2007).  Of note, this disparity appears to be related to 
the costs of the prescription medications (Adams et al., 2013; Gellad et al., 2007; 
Goldman, Joyce, & Zheng, 2007; McClelland et al., 2013; Turner, Hollenbeak, Weiner, 
Have, & Roberts, 2009) rather than just race alone.   
 
These three issues (access, use, and adherence) complicate the picture of race and 
CACHES.  Due to socioeconomic reasons, minorities are less likely to have access to and 
be able to purchase prescription medications.  A lack of access to medications would 
reduce the risk of having excess medications stockpiled in the home.  However, when 
able to access prescribed medications, minority patients potentially are less adherent to 
prescribed regimens, which could contribute to an increased risk of the accumulation of 
unused medications.  The CACHES model identifies race as a risk for CACHES, but 
recognizes it is just one characteristic of many that may place the individual at risk for 
stockpiling unused medications in the home.   
 
 
 Age.  The CACHES model identifies advanced age (≥ 65 years of age) as placing 
the individual at higher risk for the accumulation of unused and expired medications in 
his/her home.  The U.S. population will see an estimated 147% increase in the older adult 
population, from 12% in 2000 to a projected 21% in 2050 (Fulton & Allen, 2005).  Older 
adults are significant consumers of health care in comparison to any other age group 
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(Bartholow, 2012; Carrie et al., 2006; Junius-Walker et al., 2006).  Older adults are more 
likely to have multiple comorbid conditions, seek care from multiple providers, and use 
multiple pharmacies (Boparai & Korc-Grodzicki, 2011; Shin et al., 2009; Wasserfallen et 
al., 2003).  A third of the total prescription medications dispensed in the United States are 
dispensed to older adults (Mansur, Weiss, & Beloosesky, 2008; Werder & Preskorn, 
2003).  In addition, on average, older adults are responsible for 40% of the total over-the-
counter medications purchases (Fulton & Allen, 2005).  More than half of older adults 
surveyed take 5 or more medications, when combining prescription, over-the-counter, 
and supplements (Bolle et al., 2008; Boparai & Korc-Grodzicki, 2011; Fulton & Allen, 
2005; Qato et al., 2008; Torrible & Hogan, 1997).  In the state of Tennessee, older adults 
filled 42.7 prescriptions per year compared to 15.3 for people ages 19-64 and 3.1 for 
people ages 0-18 (Kaiser Family Foundation, 2010b).  Based on these data, the CACHES 
model proposes older age (≥ 65 years old) increases the individual’s risk for the 
accumulation of unused and expired medications in the home (Morgan, 2001).   
 
 
 Comorbid conditions.  Comorbid conditions is defined as having multiple, 
concurrent, chronic diagnoses and diseases.  Patients with comorbid conditions use more 
prescription medications (Anderson & Horvath, 2004; Carrie et al., 2006; Lehnert et al., 
2011; Sorensen et al., 2005) and often receive care from multiple providers across 
various settings (Anderson & Horvath, 2004; Boparai & Korc-Grodzicki, 2011; Himmel, 
Tabache, & Kochen, 1996; Lehnert et al., 2011; Mansur, Weiss, & Beloosesky, 2008; 
Prybys et al., 2002; Starfield, Lemke, Herbert, Pavlovich, & Anderson, 2005).  These 
medically complex patients often experience acute exacerbations of their underlying 
diseases, which translates into additional  visits (Anderson & Horvath, 2004; Lehnert et 
al., 2011) and repeat hospitalizations (Anderson & Horvath, 2004; Landi et al., 2004; 
Lehnert et al., 2011).   
 
This pattern of recurrent outpatient visits and hospitalizations can obscure the 
patient’s already complicated medication regimen (Anderson & Horvath, 2004; Himmel 
et al., 1996; Mansur, Weiss, & Beloosesky, 2008).  It is not unusual for up to 50% 
(Himmel et al., 1996; Mansur, Weiss, & Beloosesky, 2008) of a patient’s “at home” 
medications to be changed during a hospitalization.  In addition, upon discharge, up to 
25% (Himmel et al., 1996) to 37.5% (Mansur, Weiss, & Beloosesky, 2008) of the pre-
admission medications are not restarted.  This can contribute to a patient’s confusion as 
to which medications he/she should be taking post hospitalization.   
 
 Drug return studies in the United Kingdom (Edwards, 1982; Langley et al., 2005), 
Canada (Cameron, 1996; Torrible & Hogan, 1997), Europe (Almarsdottir & Asgeirsson, 
2009; Coma et al., 2008; Ekedahl, 2006; Wasserfallen et al., 2003), the Middle East 
(Abahussain, Ball, & Matowe, 2006), New Zealand (Braund, Gn, & Matthews, 2009; 
Braund, Peake, & Shieffelbein, 2009; James, Helms, & Braund, 2009), and the United 
States (Garey, Johle, Behrman, & Meuhauser, 2004; Morgan, 2001; Ruhoy & Daughton, 
2008) found participants cited provider-initiated changes to medication regimens as one 
of the most common reasons for returning unused medication to be disposed.  
Extrapolating from these data, a patient with multiple comorbid conditions is likely being 
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treated by multiple providers across multiple settings and has a higher frequency of 
health care visits.  This, in turn, increases the chances of multiple changes to the patient’s 
medication regime.  For these reasons, the CACHES model identifies comorbid 
conditions as a factor placing the individual at higher risk for stockpiles of unused 
medications in the home setting.   
 
 
 Polypharmacy.  Adults with multiple comorbidities are at increased risk for 
polypharmacy (Green et al., 2007; Linjakumpu et al., 2002; Mansur, Weiss, & 
Beloosesky, 2008; New England Healthcare Institute, 2009; Prybys et al., 2002; Werder 
& Preskorn, 2003).  Polypharmacy has been defined in a variety of ways in the scientific 
literature (Fulton & Allen, 2005; Hajjar et al., 2007; Hofer-Ducklemann, 2012; 
Linjakumpu et al., 2002; Veehof, Stewart, Haaijer-Ruskamp, & Jong, 2000).  One 
common definition for polypharmacy is taking medications that are not clinically 
indicated (Fulton & Allen, 2005; Hajjar et al., 2007; Prybys et al., 2002; Sorensen et al., 
2004; Veehof et al., 2000).  Another common definition is taking five or more concurrent 
medications whether clinically indicated or not (Fulton & Allen, 2005; Haider, Johnell, 
Weitoft, Thorslund, & Fastbom, 2008; Junius-Walker et al., 2006; Linjakumpu et al., 
2002; Werder & Preskorn, 2003).  In the context of the CACHES model, the latter 
definition of polypharmacy will be used.   
 
Polypharmacy contributes to poor adherence to prescribed medication regimens 
(Dunbar-Jacob & Mortimer-Stephens, 2001; Mansur, Weiss, & Beloosesky, 2008; New 
England Healthcare Institute, 2009; Prybys et al., 2002; Sorensen et al., 2005; Witticke, 
Seidling, Lohmann, Send, & Haefeli, 2013).  As the number of concurrently prescribed 
medications increases, the likelihood of the patient taking all medications as prescribed 
decreases (Hajjar et al., 2007; New England Healthcare Institute, 2009; Sorensen et al., 
2005; Witticke et al., 2013).  This incomplete consumption of all prescribed medications 
leads to the accumulation of unused and expired medications (Barat et al., 2000; 
Sorensen et al., 2005).  The CACHES model proposes a direct relationship between the 
individual experiencing polypharmacy and the development of CACHES in the home 
(Barat et al., 2000).   
 
 
 Nonadherence.  In the scientific literature, nonadherence is another term with 
several different definitions and methods of measurement (Fine et al., 2009).  The term 
nonadherence has been defined as one or all of the following patient behaviors: a) not 
filling a prescription, b) taking less than the prescribed dosage, c) taking more than the 
prescribed dosage, and d) filling the prescription but failing to take any of the prescribed 
dosage (Fine et al., 2009; Mansur, Weiss, Hoffman, Gruenewald, & Beloosesky, 2008).  
Estimates of nonadherence to medication regimens in patients with chronic diseases 
ranges from 50 to as high as 60% (Choudhry et al., 2009; Dunbar-Jacob & Mortimer-
Stephens, 2001; Wasserfallen et al., 2003; Wilke et al., 2012).  Measurements of 
nonadherence include a) patient self-report of taking medications as prescribed and/or 
number of missed doses (Fine et al., 2009; Grynmonpre, Didur, Montgomery, & Sitar, 
1998), b) provider pill-counts (Fine et al., 2009; Grynmonpre et al., 1998), and c) using 
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pharmacy claims to determine if the patient has filled his/her prescription per the 
prescribed schedule (Choudhry et al., 2009; Fine et al., 2009; Grynmonpre et al., 1998; 
Martin et al., 2009; Wilke et al., 2012).  Each of these methods of measurement has 
strengths and weakness.  Patient self-report of adherence can be biased due to patients 
desiring to be perceived as adherent.  Pill counts are an indirect measure of adherence and 
presume the absence of a pill/capsule equates to that dose being both ingested by the 
patient, as well as being ingested at the correct prescribed dosage/frequency.  Finally, 
while pharmacy claims serve as direct evidence the patient is purchasing the prescribed 
medication, they do not attest to whether the medications are, in fact, being taken by the 
patient once he/she is at home.   
 
Regardless of these issues of definition and measurement, nonadherence is cited 
as a common reason for unused medications in the home (Bound & Voulvoulis, 2005; 
Coma et al., 2008; Mackridge & Marriott, 2007; Sorensen et al., 2004; Sorensen et al., 
2005).  In the CACHES model, nonadherence increases the risk of the accumulation of 
unused and expired medications in the home (Barat et al., 2000; Langley et al., 2005; 
Sorensen et al., 2004).   
 
 
 Drug costs.  Increases in the percentage of total health care dollars spent on 
prescription medications versus other health care services has led insurance companies to 
shift costs to the health care consumer (Kaiser Family Foundation, 2010a).  This 
increased financial burden affects prescription drug use with an inverse relationship 
between out-of-pocket expenses and a patient’s prescription drug use (Kaiser Family 
Foundation, 2010a; Thomas, Wallack, Lee, & Ritter, 2002).  In response to decreased 
revenues, insurance plans incentivize the use of 90-day supplies (Ruhoy & Daughton, 
2008) or mail order (Ruhoy & Daughton, 2008; Thomas et al., 2002) prescription plans 
by offering the consumer lower copayments.  Interim changes to the patient’s medication 
regimen, by a health care provider due to inadequate response or by the patient self-
terminating the medication due to adverse effects, make the previous prescription 
obsolete (Daughton & Ruhoy, 2008; Langley et al., 2005; Ruhoy & Daughton, 2008).  As 
a result, the patient is left with multiple doses of unused medication, which contributes to 
an accumulation in the home (Daughton & Ruhoy, 2008; Langley et al., 2005; Ruhoy & 
Daughton, 2008; Steiner et al., 1993).  The CACHES model reflects this relationship with 
drug costs increasing risk of unused medications in the home.   
 
 
 Drug hoarding.  Stockpiling, also known as drug hoarding, behaviors have a 
direct contributory affect to the development of CACHES.  Hoarding behavior is defined 
as holding onto unused medications past their expiration date and/or prescribed time of 
use (Bolle et al., 2008; Ellis & Mullan, 2009; Ruhoy & Daughton, 2008; Sorensen et al., 
2004; Wazaify, Shields, Hughes, & McElnay, 2005).  The motivation for hoarding is 
multifaceted including desire for cost savings, saving in anticipation of a future need for 
the medication, and wanting to limit pollution via improper medication disposal (Bolle et 
al., 2008; Kotchen et al., 2009).   
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 With increasing cultural awareness of the environmental impact of improper 
disposal of medications (Abrons et al., 2010; Kotchen et al., 2009), some patients are 
hoarding medications due to a lack of  access to environmentally friendly disposal 
options in their community.  Concerned about the potential consequences of sewering 
unused medications (Abrons et al., 2010; Kotchen et al., 2009; Seehusen & Edwards, 
2006), patients are left with no other option than to stockpile these medications in their 
closets, medicine and kitchen cabinets (Seehusen & Edwards, 2006; Sorensen et al., 
2005).  Hoarding of unused medications contributes to the formation of CACHES, which 
place the individual at risk for adverse outcomes including adverse drug events, 
accidental poisonings, and poor health outcomes related to non-adherence (Goldsworthy, 
Schwartz, & Mayhorn, 2008; Sorensen et al., 2005, 2006).   
 
 
 Drug sharing.  Studies in the U.S. (Daniel, Honein, & Moore, 2003; Garnier et 
al., 2010; Goldsworthy et al., 2008; McCabe, Boyd, & Teter, 2006; Petersen, Rasmussen, 
Daniel, Yazdy, & Honein, 2008; Seehusen & Edwards, 2006) and internationally 
(Abahussain et al., 2006; Ellis & Mullan, 2009) reveal a common theme of individuals, 
across the lifespan (Daniel et al., 2003; Ellis & Mullan, 2009; Goldsworthy et al., 2008; 
Petersen et al., 2008), holding onto unused medications with the intent to share 
prescription medications with family members or friends (Bolle et al., 2008; Daniel et al., 
2003; Ellis & Mullan, 2009; Garnier et al., 2010; Goldsworthy et al., 2008; McCabe et 
al., 2006; McCabe, Cranford, Boyd, & Teter, 2007; Seehusen & Edwards, 2006; B. 
White, Blease, & Bishop, 2006).  Common classes of “shared” medications include 
allergy medications, antibiotics, stimulants, opioids, and benzodiazepines (Bolle et al., 
2008; Garnier et al., 2010; Goldsworthy et al., 2008; McCabe et al., 2006; McCabe et al., 
2007; Petersen et al., 2008).  The CACHES model identifies drug sharing as a risk factor 
for the stockpiling of medications in the home setting.   
 
 
 Perceptions of medication safety.  As mentioned above, individuals across the 
lifespan hoard medications with the intent to self-medicate (Bolle et al., 2008; 
Goldsworthy et al., 2008) and/or share their medications with friends and family 
members for reasons that are both therapeutic (Daniel et al., 2003; Goldsworthy et al., 
2008; Petersen et al., 2008) and non-therapeutic (Daniel et al., 2003; Garnier et al., 2010; 
Goldsworthy et al., 2008; McCabe et al., 2007; Petersen et al., 2008; B. White et al., 
2006).  These practices carry an implicit perception, by both the individual sharing and 
the individual borrowing the medication, of the general “safety” of these prescription and 
OTC medications.  The National Institute on Drug Abuse (NIDA) “Monitoring the 
Future” survey shows a growing trend in youths’ perceptions of prescription and over-
the-counter medications not being risky due to their legitimate therapeutic uses (Johnston, 
O'Malley, Bachman, & Schulenberg, 2011; Office of National Drug Control Policy, 
2011).  This perception is also common in the adult population (Bolle et al., 2008; Daniel 
et al., 2003; Goldsworthy et al., 2008).  Youth and adults are self-medicating and/or 
abusing their own or other people’s supply of unused medications with little 
comprehension for the potential adverse side effects (Bolle et al., 2008; Daniel et al., 
2003; Langley et al., 2005; Wazaify et al., 2005).  The CACHES model identifies this 
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misperception of the safety of prescription medications and OTCs as contributing to the 
retention of used medications in the home with the intent to share and/or use for non-
prescribed purposes.   
 
 
Geographic location.  To date there are a handful of studies examining the 
connection between geographic location (rural versus urban) and prescription medication 
use (Carrie et al., 2006; Grymonpre & Hawranik, 2008).  However, there is a dearth of 
studies examining the relationship between an individual’s geographic location as a risk 
for stockpiling medications in the home.  In contrast, geographical patterns of 
prescription drug abuse and misuse have received substantial attention (Brownstein, 
Green, Cassidy, & Butler, 2010; Cicero, Dart, et al., 2007; Cicero, Surratt, Inciardi, & 
Munoz, 2007; McCabe, 2005; McCabe, Boyd, & Teter, 2005; Substance Abuse and 
Mental Health Services Administration, 2005, 2010d, 2011b, 2012).  Many prescription 
drug abusers gain access to their drugs of choice via their own, their family member’s, or 
a friend’s home supply.  The CACHES model proposes geographic location (classified as 
Zip code) has a direct relationship with the individual’s risk for CACHES – a problem 
found in multiple regions across the United States (Cicero, Dart, et al., 2007; McCabe, 
2005; McCabe et al., 2005; Substance Abuse and Mental Health Services Administration, 
2010b, 2011c, 2012).   
 
Researchers have sought to identify geographical patterns associated with specific 
types of prescription drug misuse/abuse through mapping population level data 
(Brownstein et al., 2010; Cicero, Dart, et al., 2007; Cicero, Surratt, et al., 2007; Young, 
Havens, & Leukefeld, 2012).  Multiple studies identify rural populations as having 
greater risk of prescription drug abuse/misuse than larger urban populations (McCabe et 
al., 2005; Substance Abuse and Mental Health Services Administration, 2012).  However, 
there are important regional and local variations depending on availability of prescription 
drugs through both licit (prescribed by health care provider) and illicit (illegal drug trade) 
channels (Cicero, Surratt, et al., 2007).  The CACHES model builds on these previous 
studies identifying geographic location as a risk factor for the formation of CACHES.   
 
 
CACHES Model: Adverse Outcomes 
 
The right-hand side of the CACHES conceptual framework addresses adverse 
outcomes related to CACHES as experienced by the individual, the health care and 
criminal justice systems, and the ecosystem.  Adverse outcomes affecting the individual 
include accidental poisonings, misuse or abuse of medications, and adverse drug events.  
Costly emergency room visits and hospitalizations related to treatment of accidental 
poisonings, adverse drug events, overdoses, and medication misuse are a fiscal burden 
and adverse outcome for the health care system.  In addition, an increasing number of 
admissions to substance abuse treatment facilities for prescription drug abuse place 
financial strain on the health care system.  Theft of controlled substances from 
individuals' homes contributes to increased costs to the criminal justice system.  Local, 
state, and federal criminal justice systems struggle to manage the costs associated with 
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the prescription drug-related arrests and incarcerations.  Finally, limited disposal options 
lead to improper disposal practices such as flushing or placing medications in the trash.  
This introduces APIs into the water supply, ultimately contributing to pollution of the 
larger ecosystem.   
 
 
Individual 
 
 On the right-hand side of the CACHES model (Figure 2-1), the individual is 
identified as at risk for adverse outcomes secondary to his/her exposure to CACHES.  
Trends in national and state data sets, as provided by the SAMHSA, ONDCP, and DEA 
websites, offer evidence of the connection between adverse individual health outcomes, 
including poisonings, deliberate misuse or abuse of prescription medications, and adverse 
drug events.   
 
 
 Poisonings.  In the home environment, unsafe storage and easy access to 
medications pose a risk to both humans and pets (Bolle et al., 2008; Daughton, 2010a; 
Dymowski & Uehara, 1987; Gray-Winnett et al., 2010; Langley et al., 2005; McFee & 
Caraccio, 2006; Meyer et al., 2007; Substance Abuse and Mental Health Services 
Administration, 2010a).  Accidental or unintentional poisonings are defined as the 
unintentional ingestion of or exposure to a substance, which ultimately results in harm 
(American Association of Poison Control Centers, n.d.; Dymowski & Uehara, 1987; 
Meyer et al., 2007; Substance Abuse and Mental Health Services Administration, 2010a).  
Bronstein et al. (2010) reported a retrospective review of accidental poisonings in 
households called into poison control centers.  Forty-six percent of these calls were 
related to unintentional exposure to prescription and OTC medications (Bronstein et al., 
2010).  In young children, unintentional medication poisonings resulting in Emergency 
Department (ED) visits occurred twice as often as ED visits related to exposure from 
other household products (Schillie et al., 2009; Substance Abuse and Mental Health 
Services Administration, 2010a).  Over 80% of ED admissions are because an 
unsupervised child found and consumed medicines (Schillie et al., 2009).  For 
adolescents (ages 13-19), 88% of fatalities reported in 2009 to the Poison Control Centers 
were related to pharmaceuticals (Bronstein et al., 2010).  The increasing trend of 
accidental poisonings from prescription drug exposure and the increasing number of 
prescriptions per person hints at a potential relationship between these two variables.  The 
CACHES model draws a direct relationship between the number of unused medications 
found in home and the risk for accidental poisonings (Langley et al., 2005) .   
 
 
  Misuse and abuse of controlled substances.  In the CACHES model, diversion 
of medications, in particular controlled substances, for misuse and/or abuse by an 
individual (i.e. family member or friend) is an associated adverse outcome of CACHES 
(Daughton & Ruhoy, 2013; Gray-Winnett et al., 2010; Langley et al., 2005; McCabe et 
al., 2007; Ruhoy & Daughton, 2008; B. White et al., 2006).  Multiple studies note easy 
access to controlled substances in the home, where family members frequently do not 
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lock up or store controlled substances in a safe location (Bolle et al., 2008; McFee & 
Caraccio, 2006).  Diversion of these prescription drugs for misuse and abuse is a 
significant issue in the U.S. affecting individuals across the lifespan and all 
socioeconomic groups (Garnier et al., 2010; Hall et al., 2008; McCabe et al., 2006; 
McCabe et al., 2007; Office of National Drug Control Policy, 2008, 2011; Substance 
Abuse and Mental Health Services Administration, 2011c; B. White et al., 2006; 
Wisniewski et al., 2008).  The Substance Abuse and Mental Health Services 
Administration (SAMHSA), define nonmedical use as the diversion and misuse/abuse of 
controlled substances for the purpose of getting high (Substance Abuse and Mental 
Health Services Administration, 2011c).   
 
  Youth and young adult nonmedical use of prescription drugs increased by 20.2% 
from 2002 to 2009 (Johnston et al., 2011).  SAMHSA’s 2009 National Survey on Drug 
Use and Health (NSDUH) reports recent initiates, or first-time nonmedical users of pain 
relievers, to be second only to marijuana in persons 12 years and older (Substance Abuse 
and Mental Health Services Administration, 2010c).  Breaking down the NSDUH data by 
state, Tennessee is one of five states showing a significant increase in the non-medical 
use of opioid pain relievers in persons 12 and older (Substance Abuse and Mental Health 
Services Administration, 2010c).  Over 46,000 adolescents reported nonmedical use of 
pain relievers in the past 12 months (Substance Abuse and Mental Health Services 
Administration, 2010c).   
 
 Misuse and abuse of prescription medications also are becoming more prevalent 
in older adults (Blazer & Wu, 2009; Han, Gfroerer, & Colliver, 2009; L. Wu & Blazer, 
2011).  In particular, the generation of adults born between 1946 to 1964, also known as 
the Baby Boomer cohort, is considered to be at increased risk for nonmedical use of 
prescription medications and illicit substances (Colliver, Compton, Gfroerer, & Condon, 
2006).  This generational effect is believed to be secondary to diminishing negative 
attitudes toward drug use (Blazer & Wu, 2009; Colliver et al., 2006; Han et al., 2009; 
Substance Abuse and Mental Health Services Administration, 2010c; L. Wu & Blazer, 
2011).  A national survey of individuals entering into substance abuse treatment facilities 
identified alcohol as the most common reason for admission to treatment facilities in 
persons 50 years or older; however, opiates were a close second (Substance Abuse and 
Mental Health Services Administration, 2007).  Opiates were listed by those 65 years and 
older as the primary abused substance in 10.5% of admissions for treatment in 2005, 
which is up from 6.6% in 1995 (Substance Abuse and Mental Health Services 
Administration, 2007, 2010d).   
 
 An additional concerning trend is the number of individuals fatally overdosing on 
prescription medications in the setting of nonmedical use (Paulozzi & Xi, 2008; 
Wisniewski et al., 2008; Wysowski, 2007).  In 2008, for the first time ever, fatal 
poisonings (all ages) surpassed motor vehicle accidents as the number one cause of 
accidental death in the United States (Warner, Chen, Makuc, Anderson, & Minino, 2011).  
According to the Centers for Disease Control (CDC) National Center for Health Statistics 
(NCHS), 9 out of 10 poisoning deaths were caused by drugs (Warner et al., 2011), with 
more than 40% involving opioid medications (Warner et al., 2011).  In the CACHES 
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model, exposure to easily accessible controlled substances in the home places the 
individual at risk for misusing and/or abusing controlled substances and, in some cases, 
fatal drug overdoses.   
 
 
 Adverse drug events.  In the CACHES model, excess unused medications in the 
home place the individual at risk for ADEs.  An ADE is defined as a negative health 
outcome secondary to medication consumption (Boparai & Korc-Grodzicki, 2011; 
Sorensen et al., 2004).  ADEs can vary in severity.  On the milder end of the ADE 
spectrum, a patient can experience a drug rash secondary to antibiotic allergy.  Typically, 
this requires discontinuation of the medication, but no further medical intervention.  In 
contrast, a more severe example of an ADE would be a patient experiencing significant 
bradycardia (heart rate < 40 beats per minute) secondary to taking two different beta-
blocker agents concurrently.  This latter example would result in admission to an 
emergency department and/or an inpatient hospitalization.   
 
Of note, it is difficult to determine the underlying causes of adverse drug events, 
especially in the community setting.  National data sets rely on emergency department 
personnel, who categorize ADEs as accidental, intentional, and unable to determine 
(Prybys et al., 2002).  As a result, it is difficult to tease apart if an ADE is related to a 
patient accidentally or purposefully taking a discontinued or expired medication, double-
dosing errors, or the purposeful misuse of a friend or family member’s medications – as 
often happens with opioids and benzodiazepines (Ellis & Mullan, 2009).  Furthermore, 
there is no standard mechanism to capture ADEs in community-dwelling individuals who 
do not seek medical attention, which contributes to an underestimation of the incidences 
of ADEs in the overall population (Ellis & Mullan, 2009).   
 
ADE-related admissions to emergency departments and inpatient hospitalizations 
have risen steeply over the last 10 years (Ellis & Mullan, 2009; Lucado, Paez, & 
Elixhauser, 2011; Sorensen et al., 2004; Substance Abuse and Mental Health Services 
Administration, 2010b, 2011a).  Older adults are more likely to be managing multiple 
comorbid conditions with multiple medications prescribed by multiple providers (Boparai 
& Korc-Grodzicki, 2011).  Consequently, they are at risk for drug-drug interactions 
(Boparai & Korc-Grodzicki, 2011; Sorensen et al., 2004; Werder & Preskorn, 2003), 
which makes them seven times more likely to be admitted for treatment of sequelae 
related to an ADE (Lucado et al., 2011; Prybys et al., 2002; Werder & Preskorn, 2003).  
Prybys et al. (2002) identified a precipitous increase in risk from 13 to 82% for an 
adverse drug event when comparing patients taking 2 versus ≥ 7 medications (Prybys et 
al., 2002).  Adding to the problem, patients are self-medicating with over-the-counter 
medications (Fulton & Allen, 2005).   
 
CACHES of unused medications in the home introduce the possibility of 
inadvertent mixing of current and discontinued medications (Prybys et al., 2002; 
Wasserfallen et al., 2003) as well as inappropriate use for self-medication (Barat et al., 
2000; Ellis & Mullan, 2009; Sorensen et al., 2004).  This, in turn, can lead to medication 
errors including consumption of duplicate classes of medications, taking a previously 
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discontinued medication, taking incompatible medications, and/or double dosing of the 
same medication (Sorensen et al., 2004; Wasserfallen et al., 2003).  In the CACHES 
model, each of these scenarios carries an increased risk for the individual to experience 
an adverse drug event (Barat et al., 2000; Sorensen et al., 2004; Wasserfallen et al., 
2003).   
 
 
Health Care System 
 
 The individual exposed to CACHES is at risk for adverse outcomes including 
poisonings, prescription drug misuse/abuse, and adverse drug events.  Oftentimes, the 
affected individual accesses the health care system seeking treatment for the sequelae 
associated with these adverse outcomes.  In the CACHES model, the individual has a 
direct and negative impact on the HCS.  Increased utilization of health care resources 
include admissions to the ED, hospital, or substance abuse treatment centers for treatment 
of: poisonings; adverse drug events, misuse of controlled substances; and substance abuse 
issues (Birnbaum et al., 2006; Gilson & Kreis, 2009; Hohl et al., 2011; Mil, Schulz, & 
Tromp, 2004; National Drug Intelligence Center, 2011b; Strassels, 2009; Substance 
Abuse and Mental Health Services Administration, 2010d; A. White et al., 2005).  In 
addition, CACHES indirectly represent wasted health care resources.  Nonadherence to 
prescribed medical regimens results in unused medications.  In essence, these unused 
medications represent undertreated and untreated chronic health problems (Almarsdottir 
& Asgeirsson, 2009; Coma et al., 2008; Garey et al., 2004; Langley et al., 2005).   
 
 
  Increased utilization of health care resources.  The CACHES model identifies 
increased utilization of health care resources as an adverse outcome related to CACHES.  
Utilization includes patients accessing the Emergency Department, hospital, primary care 
provider office, and substance abuse treatment center.   
 
  In 2009, adverse drug events were responsible for approximately 4.6 million 
Emergency Department visits (Substance Abuse and Mental Health Services 
Administration, 2010b).  These ADEs were either attributed to prescription drug 
misuse/abuse or an adverse reaction to taking a prescribed medication (Substance Abuse 
and Mental Health Services Administration, 2010b).  Patients admitted for treatment of 
an adverse drug event stay in the hospital longer and require more outpatient care when 
compared to patients without an adverse event (Hohl et al., 2011).  Estimated hospital 
expenditures related to treatment of adverse drug events range from $2.2 to $5.6 billion a 
year (Hohl et al., 2011) and place a financial burden on the health care system.   
 
  SAMHSA’s Drug Abuse Warning Network (DAWN) tracks the number of 
Emergency Department visits related to the nonmedical use of prescription drugs 
(Substance Abuse and Mental Health Services Administration, 2010b, 2011b).  
Nonmedical use is defined by the Centers for Disease Control (CDC) as “taking a higher-
than-recommended dose, taking a drug prescribed to another person, drug-facilitated 
assault, or documented misuse or abuse” (Center for Disease Control and Prevention, 
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2010, p. 1).  The DAWN report showed a 111% increase in ED visits related to 
nonmedical use from 2004 to 2008 (Substance Abuse and Mental Health Services 
Administration, 2010b).  In addition to increased use of emergent health care facilities for 
the sequelae related to the nonmedical abuse of prescription drugs (Birnbaum et al., 2006; 
Gilson & Kreis, 2009; Strassels, 2009), several studies note increased utilization of 
outpatient services.  White et al. (2005) found opioid abusers averaged 18.7 clinic visits 
per year compared to 7 by non-opioid abusers .   
 
  Between 2004 and 2005, an estimated 71,224 children younger than 18 years of 
age were seen in EDs because of medication poisonings (Schillie et al., 2009).  Of these 
cases, 156,613 (22%) of ED visits resulted in hospitalization or transfer to another facility 
(Schillie et al., 2009).  Poisonings led to an estimated $248 million in medical and 
productivity costs (Centers for Disease Control and Prevention, 2011).   
 
  In 2010, nonmedical use of prescription opiates was the second most prevalent 
reported reason for admission to a treatment facility for persons age 12 and older 
(Substance Abuse and Mental Health Services Administration, 2010d).  The NDIC 
estimates the total costs for substance abuse treatment (including detoxification, 
residential, and outpatient programs) in 2007 to be approximately $3 billion (National 
Drug Intelligence Center, 2011b).  Of note, many patients entering substance abuse 
treatment programs report abusing multiple substances.  As a result, the costs calculated 
by the NDIC do not separate out the treatment costs for both illicit (heroin, cocaine, 
methamphetamine, marijuana) and prescription drug abuse (National Drug Intelligence 
Center, 2011b).  However, it is likely that prescription drugs account for a substantial 
portion of the $3 billion dollars of health care costs.   
 
It is a challenging task to calculate the total health care costs associated with 
prescription drug misuse and abuse, adverse drug events, and poisonings (Strassels, 
2009).  However, the data imply utilization costs are considerable.  These costs, along 
with loss of life, must be factored into the financial equation when looking at the 
economic burden to the health care system (Gilson & Kreis, 2009; Strassels, 2009; A. 
White et al., 2005; Wysowski, 2007).  The CACHES model identifies increased health 
care utilization as an adverse outcome related to unused medications in the home.   
 
 
  Unused medications as wasted health care dollars.  CACHES of unused and 
expired medications also reflect direct and indirect waste of health care dollars (Cameron, 
1996; Mackridge & Marriott, 2007; Morgan, 2001; New England Healthcare Institute, 
2009; Roebuck, Liberman, Gemmill-Toyama, & Brennan, 2011).  Direct costs include 
the costs represented by the unused medications themselves (Langley et al., 2005; 
Mackridge & Marriott, 2007; Morgan, 2001; K. White, 2010).  Multiple studies have 
attempted to calculate these costs through cataloging unused drug returns.  For example, 
Cameron (1996) estimated the costs of unused medications, collected in Alberta 
providence over an 8-week period, equaled an estimated $710,000 U.S. dollars.  A five-
week drug return campaign in Iceland collected unused medications with an estimated 
value of 198,000 Euros (Almarsdottir & Asgeirsson, 2009).  In Britain, a two-month 
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count of unused medications returned to local pharmacies and General Practitioner 
surgeries in Eastern Birmingham totaled £33, 608 (Mackridge & Marriott, 2007).  A 
Houston pharmacy collected unused medications to the total of $26,000 U.S. dollars over 
a six-month period (Garey et al., 2004).  It is important to note these costs estimates are 
likely underestimates.  None of these studies were designed to calculate the costs of 
additional unused and expired medications still left in the home (Almarsdottir & 
Asgeirsson, 2009; Cameron, 1996; Garey et al., 2004; K. White, 2010).   
 
CACHES of unused and expired medications also represent the indirect costs 
associated with nonadherence to prescribed pharmacological interventions for the 
management of acute and chronic conditions (Dunbar-Jacob & Mortimer-Stephens, 2001; 
Hovstadius & Petersson, 2011; New England Healthcare Institute, 2009; Roebuck et al., 
2011; Ruhoy & Daughton, 2008; Sorensen et al., 2005; Wasserfallen et al., 2003).  
Nonadherence is an umbrella term which can include a wide range of medication taking 
behaviors including taking none of the prescribed medication, taking less than the 
prescribed dosage, and taking more than the prescribed dosage.  For the purposes of the 
CACHES model, the first two behaviors are considered to contribute to the accumulation 
of unused medications in the home setting.   
 
 
Criminal Justice System 
 
In the CACHES model, the criminal justice systems (CJS) are defined as those 
systems involved in the investigation, persecution, and imprisonment of individuals 
committing crimes as well as the costs associated with the victimization of the individual 
secondary to drug-related crime.  Joranson and Gilson (2005) analyzed annual data from 
2000 to 2003 from the Drug Enforcement Administration (DEA) “Report of Theft or 
Loss of Controlled Substances” and found 28 million dosage units of controlled 
substances were diverted during this 3-year period .  Diversion occurred along different 
points of the supply chain including manufacturers, suppliers, pharmacies, health care 
practitioners’ offices, and substance abuse treatment programs (Joranson & Gilson, 
2005).  These diversion data do not include the diversion of controlled substances from 
the home setting, as oftentimes, these crimes are not reported to local police.  The 2010 
National Survey on Drug Use and Health found among people age 12 or older who 
reported using opioids non-medically in the past year, 70% got the drug from a friend or 
relative for free (Office of National Drug Control Policy, 2008, 2011; Substance Abuse 
and Mental Health Services Administration, 2011c).   
 
Nonmedical use of opioids places a financial burden on the criminal justice 
system (Birnbaum et al., 2006; Gilson & Kreis, 2009; National Drug Intelligence Center, 
2011b).  Estimates regarding the total costs assumed by the criminal justice system range 
from $1.4 billion on issues related to nonmedical use of opioids alone (Birnbaum et al., 
2006) to $193 billion for all illicit substances – which includes nonmedical use of 
prescription drugs (National Drug Intelligence Center, 2011a, 2011b).  The National 
Drug Intelligence Center (NDIC) breaks down crime costs into three major categories: 
$1.46 billion in victim costs, $56 billion in criminal justice system costs, and $3.55 
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billion in other crime costs (National Drug Intelligence Center, 2011b).  The CACHES 
model focuses on the first two costs identifying victimization costs (drug theft, property 
damage/loss, and loss in productivity) and drug-related arrests/incarcerations as two 
significant adverse outcomes related to the presence of CACHES in the individual’s 
home.   
 
 
 Victimization costs (drug theft, property damage/loss, loss in productivity).  
The costs of victimization can be calculated in a variety of ways.  First, there is the direct 
loss of money as related to the costs of the stolen medications (National Drug Intelligence 
Center, 2011b).  Second, a broader definition of costs includes those associated with 
property damage or loss and productivity costs (victim misses work) coinciding with the 
theft of medications (National Drug Intelligence Center, 2011b).  In its 2010 report, the 
NDIC calculates the total costs at approximately $1.5 billion (National Drug Intelligence 
Center, 2011b).   
 
 
 Drug-related arrests and incarceration.  National numbers on drug-related 
arrests are collected via three surveys: the Survey of Inmates in Local Jails (SILJ), the 
Survey of Inmates in State Correctional Facilities, and the Survey of Inmates in Federal 
Correctional Facilities (National Drug Intelligence Center, 2011b).  According to the 
2006 SILJ report, 35,969 offenders admit to drug-related crimes in 2002, with an 
additional 201,662 in state and 23,333 in federal prisons (National Drug Intelligence 
Center, 2011b).  Total costs, including the arrests, investigations, and incarceration of 
these individuals, are estimated at $56 billion (National Drug Intelligence Center, 2011b).  
In 2011, there were 257 crimes related to narcotics (morphine and other narcotics) in 
Davidson County (Tennessee Bureau of Investigation, 2013).  Costs related to these 
crimes are not available.  However, the same issues of costs related to arrest, 
investigations, and incarceration would hold true at the local level as do at the state and 
federal.   
 
 
Ecosystem 
 
 In the CACHES model, the ecosystem is defined as the local and/or regional 
ecosystem including microorganisms (bacteria), macro-organisms (flora, amphibians, 
reptiles, and mammals), and these organisms’ natural habitats (water, plants, earth).  
Referring to the CACHES model (Figure 2-1), there is an interactive (double-headed 
arrow) relationship between the ecosystem and the individual.  Improper disposal 
practices by individuals in the community introduce active pharmaceutical ingredients 
(APIs) directly into the ecosystem polluting the watersheds and streams that feed the 
drinking water supply.  Currently, water-processing plants do not have the technology to 
remove these trace APIs from the drinking water (Snyder, Westerhoff, Yoon, & Sedlak, 
2003; Westerhoff et al., 2005) and, as a result, the individual and his/her larger 
community are exposed to these APIs.   
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Options for individuals to dispose of unused or expired medications are limited in 
the U.S., thereby resulting in improper disposal practices such as throwing out in the 
trash and sewering (Abrons et al., 2010; Daughton & Ruhoy, 2008; Environmental 
Protection Agency, 2010; Glassmeyer et al., 2009; Kotchen et al., 2009; Kuspis & 
Krenzelok, 1996; Ruhoy & Daughton, 2007; Seehusen & Edwards, 2006).  Over the last 
20 years, water-sampling analyses have detected the presence of APIs in trace amounts in 
U.S. streams, watersheds, and drinking water (Barnes et al., 2008; Daughton & Ruhoy, 
2008; Environmental Protection Agency, 2010; Kidd et al., 2007; Snyder et al., 2003; 
Stackelberg et al., 2004; Westerhoff et al., 2005).  Concerns over the potentially harmful 
effects of APIs on the ecosystem have been gaining momentum in the scientific and lay 
community (Abrons et al., 2010; Daughton, 2010b; Daughton & Ruhoy, 2008; Furtula et 
al., 2010; Glassmeyer et al., 2009; Kidd et al., 2007; Orlando et al., 2004; Roig et al., 
2009; Stackelberg et al., 2004; Westerhoff et al., 2005; M. Wu & Janssen, 2011).  To 
date, environmental studies of APIs in the environment have revealed exposure to these 
trace pharmaceuticals, in particular estrogenic hormones, result in the feminization of 
male fish of certain fish species (Bound & Voulvoulis, 2005; Gross-Sorokin et al., 2006; 
Jobling et al., 1998; Kidd et al., 2007; Orlando et al., 2004).  Microbe resistance 
secondary to bacteria’s exposure to trace antibiotics in the water supply is another 
adverse outcome of APIs in the ecosystem (Furtula et al., 2010; Schwartz et al., 2006; 
Zhang et al., 2009).  Finally, higher-level animals, in particular predators, have 
experienced adverse health outcomes secondary to the consumption of prey that have 
accumulated trace amounts of APIs (Oaks et al., 2006; Roig et al., 2009).   
 
 Environmentalists continue to examine the long-term effects of APIs on the health 
of both the ecosystem and humans (Daughton & Ruhoy, 2009b; Furtula et al., 2010; 
Larsson, Pedro, & Paxeus, 2007; Musson & Townsend, 2009; M. Wu & Janssen, 2011).  
These efforts are hindered by a lack of consensus on a) which routes of API introduction 
into the environment are the most problematic (Daughton & Ruhoy, 2008; Larsson et al., 
2007; Musson & Townsend, 2009), b) how best to measure the levels of APIs in the 
ecosystem (Daughton & Ruhoy, 2008; Musson & Townsend, 2009; Wennmalm et al., 
2010), c) what classes of APIs are most harmful to the micro and macro-environment 
(Daughton & Ruhoy, 2008; Larsson et al., 2007), and d) how to determine what 
concentrations and durations of exposure (acute and chronic) to APIs are harmful to 
biological life forms (Daughton & Ruhoy, 2008; Kidd et al., 2007; Larsson et al., 2007; 
Wennmalm et al., 2010).  Regardless, there is sufficient evidence to suggest exposure to 
trace pharmaceuticals in the water supply results in adverse outcomes for lower levels of 
biologic life forms in the ecosystem.  The CACHES model reflects this relationship.  
Improper disposal of medications introduce APIs into the ecosystem resulting in adverse 
outcomes.   
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CHAPTER 3.    METHODOLOGY 
 
 
Chapter 3 includes a discussion of the research design, sample size, sampling 
techniques, the research site, inclusion/exclusion criteria, study variables and operational 
definitions, instrumentation, data collection procedures, and analyses performed.   
 
 
Research Design 
 
This study was a retrospective, secondary analysis of data extracted from existing 
death scene reports, medical records, autopsy and toxicology reports, and medication data 
originally collected over the course of death scene investigations by Forensic Medical, 
PLC in Nashville, Tennessee.  Forensic Medical is a private company contracted by 
Davidson and Shelby County to provide professional forensic pathology, Medical 
Examiner, and medicolegal death investigative services for suspicious, traumatic, or 
unexpected deaths in Davidson and Shelby County.  In addition, they provide autopsy on 
a fee-for-service basis to other Tennessee counties.  This study examines the prevalence, 
size, and composition of CACHES found in decedents’ homes during the course of death 
scene investigations.  A descriptive analysis of the demographic data (gender, race, age, 
and comorbid conditions) was performed.  Additionally, the geographic locations of 
CACHES were identified.  Finally, the relationship between health care risk factors 
(number of prescribers, number of dispensaries) and CACHES was explored.   
 
 
Sample and Setting 
 
 
Sample Size 
 
The Forensic Medical, PLC Investigators and Medical Examiners were involved 
in 2,546 death scene investigations in Middle Tennessee from January 1, 2011 through 
December 31, 2011.  Of these cases, 1,146 deaths occurred outside of Davidson County 
and therefore were excluded from the sample.  Of the remaining 1,400 Davidson County 
cases, 1,190 were excluded according to the study exclusion criteria (see below).  The 
final study sample size included 210 cases of decedents with medications in the home and 
80 decedents who died at home with no evidence of medications on the death scene.   
 
 
Sample Technique 
 
This study used a convenience sampling of data obtained via a retrospective 
review of existing Forensic Medical, PLC death scene charts.  Each decedent’s chart 
included the following documents: Investigator Report, Death Certificate, and Evidence 
Sheet.  A subset of charts also included an Autopsy Report, Toxicology Report, outside 
electronic medical records, and a Medication List.   
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Site 
 
According to Tennessee Code 38-7-108,  
 
“Any physician, undertaker, law enforcement officer, or other person having 
knowledge of the death of any person from violence or trauma of any type, 
suddenly when in apparent health, sudden unexpected death of infants and 
children, deaths of prisoners or persons in state custody, deaths on the job or 
related to employment, deaths believed to represent a threat to public health, 
deaths where neglect or abuse of extended care residents are suspected or 
confirmed, deaths where the identity of the person is unknown or unclear, deaths 
in any suspicious/unusual/unnatural manner, found dead, or where the body is to 
be cremated, shall immediately notify the county medical examiner or the district 
attorney general, the local police or the county sheriff, who in turn shall notify the 
county medical examiner.  The notification shall be directed to the county medical 
examiner in the county in which the death occurred” (Tennessee Code Annotated, 
2012). 
 
Forensic Medical Management Services, PLC is a private company contracted to 
provide forensic examination of evidence collected in the case of violent, traumatic, 
suspicious, or sudden and unexpected deaths (as well in other specific circumstances 
listed in Tennessee Code 38-7-108) in Davidson and Shelby Counties.  Forensic 
Medical’s jurisdiction covers 68 out of the total 95 counties in Tennessee.  As mandated 
by the State of Tennessee Code, Forensic Medical, PLC is accredited by the National 
Association of Medical Examiners (NAME).  Forensic Medical’s 10 Medicolegal Death 
Investigators (MLDIs) and 6 Medical Examiners Board Certified Forensic Pathologists 
(MEBCFPs) follow the standards, practices, and investigative procedures as dictated by 
NAME.  The MLDIs are involved in on-scene collection of evidence, including the 
collection and cataloging of medications.  The MEBCFPs perform the following services: 
in-house external examination, autopsy (for certain required or requested cases), 
toxicology screening, and examination of any on scene evidence accompanying the body.  
All Death Certificates are completed and signed by one of the six MEBCFPs.   
 
Procedures for Forensic Medical’s involvement in a death scene investigation 
begin with a notification from local law enforcement (Police or Sheriff’s department).  
The Medicolegal Death Investigator consults with law enforcement and obtains a verbal 
report of the decedent’s demographic information, location of death, and any other 
circumstantial evidence.  If the on-scene law enforcement official is able to determine the 
name of the decedent’s health care providers, the MLDI will attempt to contact the 
provider to obtain additional information regarding the decedent’s health history.  The 
MLDI waives jurisdiction if all three of the following conditions are met: 1) the provider 
indicates the decedent’s death was not unexpected and likely due to natural causes; 2) the 
provider gives his/her verbal agreement to sign the Death Certificate; and 3) law 
enforcement reports no evidence of a homicide, suicide, or anything suspicious regarding 
the nature of the decedent’s death.  If these three conditions are not met, the MLDI 
accepts jurisdiction of the case.  Once on scene, the MDLI performs a visual examination 
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of the scene, takes pictures of the scene and body, collects evidence (including 
medications), and manually examines the body.  All observations of the death scene are 
captured in the MLDI’s written Investigator Report, as well as photographs.  The body is 
then placed into a body bag, along with any evidence collected on scene, and transported 
to the Medical Examiner’s Office for further examination by the MLDI and MEBCFP.  
The MEBCFP performs an external examination of the body, takes pictures, fingerprints 
and DNA samples, removes ballistics (if present) from the body, and collects blood and 
vitreous fluid samples for possible toxicology screening.  Medications are identified, 
cataloged and then destroyed by the MLDI.  Destruction of the medications is witnessed 
by a second MLDI.  The MEBCFP summarizes all evidence and makes a final 
determination of the cause of death, manner of death, and contributing factors to the 
death as dictated by the NAME guidelines (Hanzlick, Hunsaker, & Davis, 2002).  A 
request for copies of the decedent’s medical records is sent to likely health care facilities.  
The Investigator Report, photographs, copies of medical records, autopsy (if performed) 
and external exam report, toxicology screen results, medication list, and evidence log 
sheet are filed in paper charts maintained on site at Forensic Medical’s offices.  Data 
from these charts are also entered into DIDI – a proprietary database developed 
specifically for Forensic Medical, PLC.   
 
Per legal requirements, MLDIs follow strict procedures in the on-scene search for 
and collection of medications as evidence.  Medications found in the vicinity of or on the 
body are collected as evidence.  In addition, the MDLIs search standard medication 
storage locations including bedside tables, bedroom dresser, medicine cabinet, kitchen 
counters and cabinets, and refrigerator.  Medications must be designated as prescribed to 
the decedent; however, if the MDLI suspects the decedent’s death was directly caused by 
the ingestion of a friend/family member’s medications, those medications may also be 
collected.  Over the counter medications are collected only if there is a high suspicion 
they contributed to the cause of death.  Illicit substances found on scene are surrendered 
to law enforcement for identification, cataloging, and destruction.   
 
 
Inclusion Criteria 
 
The criteria for inclusion of subjects for this study were the following:  
 
1. Decedents who died at home in Davidson County, Tennessee during the time 
period of January 1 through December 31, 2011.   
 
2. Decedents whose cause and manner of death met the State of Tennessee’s 
legal requirements mandating investigation by the Medical Examiner’s 
(Forensic Medical, PLC) Office.   
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Exclusion Criteria 
 
The criteria for exclusion of subjects for this study were the following: 
 
1. Decedents who were younger than 18 years of age at time of death. 
 
2. Decedents who died outside of the home including hospital, prison, jail, long-
term care facility, woods, bodies of water, hotel rooms (unless identified as 
primary place of residence), or other person’s residence.  
 
3. Decedents who had an in-home death involving Hospice Care. 
 
4. Decedents requiring postmortem revision and re-issuance of Death 
Certificates by the Medical Examiner but did not have an on-scene 
investigation at the time of death. 
 
 
Variables and Operational Definitions 
 
This section identifies, defines, and operationalizes the major concepts and the 
concepts’ associated characteristics studied in this pilot study.  The study concepts and 
associated characteristics include the individual (gender, race, age, comorbid conditions, 
geographic location), the health care system (prescribers, dispensaries), and CACHES 
(prevalence, size, and composition).  In addition, this section reviews the original data 
collection and documentation procedures followed by the Medicolegal Death 
Investigators and Medical Examiner Board Certified Forensic Pathologists.   
 
 
Individual 
 
The CACHES model defines the individual as a community-dwelling person.  
Specifically, the model delineates the individual as living in a residential (rented or 
owned) structure that does not meet any of the following definitions: long term care 
facility, jail, or prison.  Decedents who died in their permanent place of residence were 
designated as a 0 in the study database.  Procedurally, the MDLI of record consults with 
on-scene law enforcement and witnesses to make a determination the location of death 
was the decedent’s permanent residence.  The Investigator Reports captured these data 
for each decedent and final determination of the decedent’s place of residence is captured 
in the Death Certificate.  The researcher compared the MLDI’s Investigator Report to the 
final Death Certificate’s report of Location of Death and Residence to ensure 
confirmation the decedent died in his/her residence and the residence met the designation 
of residential structure.   
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Gender 
 
The CACHES model defines gender as the biological designation of either female 
or male.  For the purposes of this study, gender is coded as female (0) or male (1).  The 
MEBCFP makes a gender designation based on his/her external examination and/or 
autopsy of the decedent’s body.  For the purposes of this study, gender designation 
aligned with the decedent’s gender as indicated in the Death Certificate.  The researcher 
cross referenced the MLDI’s Investigators Report and the MEBCFP’s report of the 
decedent’s gender in the Death Certificate.   
 
 
Race 
 
The CACHES model defines race according to the Death Certificate categories 
including Caucasian (0), African American (1), Hispanic (2), Asian (3), or Other (4).  
The MEBCFP and MDLI assign race category based on the decedent’s state-issued 
Driver’s License designation, family/friend report, and examination of the decedent’s 
external facial and skin characteristics.  The MEBCFP record the patient’s race on the 
Death Certificate.  The researcher used the Death Certificate designation of race for this 
secondary data analysis.   
 
 
Age 
 
The CACHES model defines age as chronological age (in years) at time of death.  
The MLDI determines the decedent’s age at time of death by subtracting the determined 
date of death from the date of birth.  Date of birth is obtained via the decedent’s state 
issued Driver’s License or other state issued identification.  The MEBCFP enters the date 
of birth and age at death into the Death Certificate.  The researcher obtained age at time 
of death from the decedent’s Death Certificate.  Birthdates were not collected by the 
researcher in order to protect the decedents’ confidentiality.   
 
 
Comorbid Conditions 
 
The CACHES model defines comorbid conditions as chronic health diagnoses 
identified in the decedent’s health history.  The researcher captured the data as free text in 
the original study database and then later grouped the comorbid conditions data into the 
following categories: psychiatric (PSYCH), substance abuse (SUBST), cognitive disorder 
(COGN), and other (OTHER).  For the first three diagnostic categories, the researcher 
designated the absence 0 or presence 1 of a psychiatric, substance abuse, or cognitive 
disorder diagnosis.  All other diagnoses not captured under these three categories were 
classified as other and totaled as a sum number.  Examples of psychiatric diagnoses 
included depression, anxiety, schizophrenia, bipolar disorder, schizoaffective disorder, 
and obsessive compulsive disorder.  Substance abuse diagnoses included illicit drugs 
(cocaine, crack cocaine, heroin, marijuana, “K2”, “Spice”, and “Bath Salts”) and licit 
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substances (alcohol, prescription drugs).  Examples of cognitive disorders/diseases 
included cerebrovascular accident, Alzheimer’s disease, Parkinson’s disease, 
frontotemporal dementia, traumatic brain injury, vascular dementia, and unspecified 
dementia.  The MLDIs and MEBCFPs obtained the decedent’s diagnostic information 
from a variety of sources.  MLDI’s on-scene interviews with family members, 
roommates, and/or neighbors were one source.  If available, the MLDI used information 
from the decedent’s prescription medications to contact the decedent’s health care 
provider(s) for verbal confirmation of the decedent’s diagnoses.  The MLDI’s 
Investigator Reports captured the data from these two main sources.  An additional 
source of the decedent’s comorbid conditions included diagnostic data obtained through 
the external examination and autopsy of the decedent’s body.  Finally, electronic medical 
records provided additional diagnostic data.  The researcher used all of the above sources 
in the process of determining the decedent’s comorbidities.   
 
 
Geographic Location 
 
The CACHES model defines geographic location as the geospatial location of the 
decedent’s primary residence and place of death.  The researcher operationalized this 
variable using the U.S. Postal Service’s 5-numbered Zip code designation.  The MDLIs 
obtain Zip code information via on-scene law enforcement report of the decedent’s 
address/location of death.  Both the Investigator Report and Death Certificate provide 
these data.   
 
 
Health Care System 
 
The CACHES model defines the health care system as the setting(s) in which the 
individual receives health care.  Examples of health care settings include primary care 
offices, specialty clinics, Emergency Departments, hospitals, substance abuse treatment 
centers, and long term care facilities.  Characteristics associated with the health care 
system include prescribers and dispensaries.   
 
 
Prescribers 
 
The CACHE model defines a prescriber as any health care provider (physician, 
nurse practitioner, physician’s assistant, or dentist) with prescriptive authority.  The 
CACHES model further identifies that as the total number of distinct prescribers 
increases, so does the individual’s risk of CACHES.  For the purposes of this study, each 
unique prescriber was identified by their last name using a free text field.  The researcher 
then summed the total number of prescribers.  The MLDIs obtain prescriber information 
directly from medication containers found at the death scene.  They enter the prescriber’s 
first and last name (if available) into DIDI, as part of the Medication List report, which is 
printed out and placed in the decedent’s paper chart file.   
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Dispensaries 
 
The CACHES model defines dispensaries as any commercial pharmacy (national 
chain pharmacies, independent pharmacies, physician clinics) where prescription and 
OTC medications can be dispensed to the individual.  In the CACHES data, the 
operationalized definition for a dispensary is the sum total of distinctly separate 
dispensaries used by the decedent.  The MLDI’s captured these original data directly 
from the medication containers found at the death scene.  They enter the dispensary name 
and phone number into DIDI, as part of the Medication List report.  The researcher 
entered the dispensaries data as both a free text entry (name of dispensary) and a 
calculated sum total of all dispensaries used by the decedent.   
 
 
CACHES 
 
The CACHES model defines CACHES as stockpiles of unused prescription and 
OTC medications found in the home setting.  For the purposes of this study, unused 
medications were operationalized as any dosages > 7 days beyond the prescribed use by 
date.  This 7-day gap accommodated for potential left-over doses associated with 
recurring prescriptions (refills).  The MLDI entered the following data (when available) 
into the Medication List: medication brand name, dosage, units, frequency, total doses 
dispensed, and total doses remaining.  The researcher performed manual calculations to 
determine if the remaining doses were medications currently in use or unused.  First, the 
researcher used the dosage, frequency, and number of doses dispensed to calculate the 
total number of days the prescription covered (10 days, 30 days, and 90 days).  Next, the 
researcher used the date dispensed to determine how many pills should be remaining at 
the time of death, if the patient had been adherent to the prescribed regimen.  Finally, the 
researcher compared the number of doses that should be remaining to the number of 
actual doses remaining.  The researcher defined any doses ≤ 7 days outside of the 
prescribed use-by date as currently in use and designated this in the study database as a 
value of 0. Any doses > 7 days outside of the use-by date were defined as unused and 
designated in the database with a 1.   
 
Additional calculations included the prevalence, size, and composition of 
CACHES.  The prevalence of CACHES in the home was calculated by dividing the 
number of subjects with CACHES by the total sample size and then multiplying by 100.  
The researcher defined the size of the CACHES according to the sum number of bottles 
or containers of unused medications found in the decedent’s home.  These data were 
available in the Medication List.  Finally, the researcher analyzed the composition of the 
CACHES by assigning each medication a classification based on the system of activity 
(cardiovascular, gastrointestinal, central nervous system, etc.) as well as a category based 
on the disease/disorder for which the medication was used.  The researcher used the 
Elsevier medication classification system to assign each medication entry a medication 
class and category.   
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Instrumentation 
 
The researcher developed the following three study-specific data extraction forms 
using Microsoft Excel®: Included_Demographics, Included_Medications, and 
Excluded_Demographics.  These forms facilitated the extraction of data from the 
Forensic Medical charts and allowed easy uploading of the data into the SPSS® 21 
statistical software package.   
 
 
Data Collection Procedures 
 
After obtaining written permission from Dr. Amy McMaster Hawes (Chief 
Medical Officer and Chief Medical Examiner for Davidson County, Nashville Location), 
the researcher met with Forensic Medical, PLC personnel Fran Wheatley (Lead 
Administrator of Davidson County Contract), Lisa Robison (Director of Administrative 
and Clerical Services, Nashville Location) and Kathy VanBuren (Administrative 
Assistant, Nashville Location) to establish a schedule and review data collection and 
privacy protection procedures.  In addition, the researcher provided a written copy of the 
study-specific privacy protection procedures.  The researcher created a Master Study List 
containing the decedents’ identifying case numbers (assigned by the Medical Examiner’s 
office during the course of the death investigation) and initials.  In addition, the 
researcher assigned each decedent a unique study number, which was included in the 
Master Study List.  The Master Study List was the only study document containing both 
the identifying case numbers and the assigned study number.  The Master Study List 
remained on site at Forensic Medical, PLC at all times over the duration of the study.  It 
was kept in the chart room, which is a locked and secure room.  The researcher followed 
this process as a precaution to ensure privacy of the decedent’s personal health 
information.  Upon completion of the pilot study, the Master Study List was destroyed on 
site at Forensic Medical, PLC.   
 
Data collection occurred from September through December, 2012.  Data 
collection techniques included a manual review and extraction of pertinent data from 
each of the decedent’s paper charts.  The researcher stored all study data in the three 
Excel® databases on an encrypted laptop.  Decedents were identified by their assigned 
study number only in this database file to ensure the protection of the decedent data.  The 
researcher collected individual Zip codes as part of the geographical mapping of the 
location the CACHES.  These data were aggregated at the Zip code level to protect the 
individual decedents’ identities.  No individual decedent’s data are reported in this 
dissertation or will be in any subsequent dissemination of the study findings.   
 
 
Data Analysis 
 
The researcher cleaned the data prior to analysis using the following values to 
designate missing data: gender (99), race (99), age (unknown), comorbid conditions (99), 
geographical location (Zip code = 99999), medication name brand (99), dosage 
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(unknown), frequency (unknown), date dispensed (unknown), number dispensed 
(unknown), number remaining at time of death (unknown), prescriber name (99), 
dispensary name (99), total number of prescribers (unknown), and total number of 
dispensaries (unknown).  The researcher analyzed the data using SPSS 21® software.   
 
SPSS 21® was used to perform simple descriptive analysis of the study sample 
demographics.  In addition, SPSS 21® was used for the analysis of specific aims one, 
two, three, four and five.  The following section will list each specific aim and the 
analyses performed for each aim.  An alpha level of 0.05 was used to determine statistical 
significance.   
 
 
Descriptive Statistics of the Study Sample 
 
Simple descriptive statistics were used to describe the study sample demographics 
(gender, race, age).  The study sample was divided into two comparison groups: 
decedents with medications (both current and unused) and decedents without medications 
in the home at the time of death.  Simple univariate frequency statistics were performed 
on each of the demographic traits listed and the distribution reported as percentages.  Age 
was categorized into ranges and then the distribution reported according to these ranges: 
less than 18 years of age, 18-35, 36-45, 46-64, and 65 and older.  In addition, the central 
tendencies (mean, median, and interquartile range) of the two sample populations’ ages 
were calculated.  Finally, the total study sample demographics (gender, race, age) were 
compared to Davidson County population using data from the U.S. Census Bureau 2000 
Census.   
 
 
Specific Aim One 
 
To describe the prevalence of CACHES found in decedents’ homes in Davidson 
County, Tennessee from January 1, 2011 through December 31, 2011.  
 
Prevalence rates are used to examine the occurrence of a particular disease or 
condition in a particular population.  Prevalence is calculated using the total number of 
subjects with a condition and dividing that number by the total number of all subjects 
(with and without a condition) in the population.  This number is then multiplied by 100 
for a final percentage.  For the purposes of this study, the subject was defined as 
decedents who lived in Davidson County, Tennessee and had a death investigation 
between January 1 - December 31, 2011.  The condition was defined as having containers 
of unused medications (CACHES) in the home.  The prevalence formula for this study 
was:  
  
Number of decedents with CACHES      x 100 
Total number of decedents in sample   
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Specific Aim Two 
 
To examine the size and composition of CACHES found in decedents’ homes in 
Davidson County, Tennessee from January 1, 2011 - December 31, 2011.  
 
 Simple univariate statistics were used to describe the size (total number of unused 
bottles or containers of medications in the decedent’s home) and composition (types of 
medication classes) of CACHES.  While the majority of medications collected were in 
their original containers (bottles, vials, metered-dose inhaler devices, tubes), some were 
found in unmarked plastic bags, bottles, weekly pill containers, or were un-contained (in 
the decedent’s pocket, on the floor, on a table/counter).  The researcher was unable to 
obtain the dispensed by date for medications not in their original pharmacy packaging 
and so these medications were not included in the CACHES calculations.  The size of 
CACHES was determined based on the sum total of individual bottle/containers of 
unused (> 7 days past use-by date) medication in each decedent’s home.  The researcher 
reported these findings as frequency statistics.   
 
For CACHES compositional calculations, the researcher classified each 
individual medication into its major system of action (cardiovascular, gastrointestinal, 
central nervous system, etc.) and disease/disorder category using the Elsevier 
classification system.  The Elsevier classification system closely reflected categorizations 
made by previous researchers reporting medication returns to pharmacies (Coma et al., 
2008; Garey et al., 2004; James et al., 2009; Langley et al., 2005; Mackridge & Marriott, 
2007) or unused medications found in the home (Ellis & Mullan, 2009; Torrible & 
Hogan, 1997; Wasserfallen et al., 2003).  The researcher used frequency statistics to 
analyze these data.   
 
 
Specific Aim Three 
 
Among decedents with medications in the home, to compare individual risk 
factors (gender, race, age, comorbid conditions) between those with CACHES and those 
without CACHES in their Davidson County, Tennessee homes from January 1, 2011 - 
December 31, 2011.   
 
The study sample was divided into two groups: those with CACHES (unused 
medications) in the home and those without CACHES (all medications found were 
currently in use at time of death).  Simple univariate descriptive statistics were used to 
describe the two sub-samples’ demographics (gender, race, age).  Frequency statistics 
were performed on each of the demographic traits listed and the distribution reported as 
percentages.  The researcher performed a Pearson’s Chi-squared analysis to determine if 
gender and race distribution differed between the two groups, CACHES versus no 
CACHES.  In addition, the researcher used an independent t-test to compare the mean 
age for decedents with CACHES versus those without CACHES.   
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The researcher categorized the total number of comorbid conditions according to 
the following ranges: 0-2, 3-4, 5-7, and 8 or more comorbid conditions.  Frequency 
statistics were performed on the comorbid totals for decedents with medications 
(currently in use and unused) in the home (n = 210), as well as for decedents with 
CACHES (n = 163) and without CACHES (n = 16).  The central tendency of total 
comorbid conditions was calculated for both the CACHES and no CACHES group.  The 
samples were skewed and therefore a Mann-Whitney analysis was performed to compare 
the medians of these two samples.  Finally, the researcher converted the free text fields 
for each of CACHES and no CACHES groups’ psychiatric, substance abuse, and 
cognitive decline diagnoses to a binary (0 = absent, 1 = present) value.  A Pearson’s Chi-
squared analysis was used to determine if CACHES were associated with a psychiatric, 
substance abuse, or cognitive disorder diagnosis.   
 
 
Specific Aim Four 
 
To describe the relationship between geographic location (Zip code) and the 
presence of CACHES in decedents’ homes in Davidson County, Tennessee from January 
1, 2011 - December 31, 2011.   
 
 Frequency statistics were performed on the number of CACHES per geographical 
location (Zip code).  Due to a small sample size, statistical analysis of the relationship 
between geographical location and CACHES was not able to be performed.   
 
 
Specific Aim Five 
 
Among decedents with medications, to compare health care system risk factors 
(number of prescribers, number of dispensaries) between those with CACHES to those 
without CACHES.   
 
Frequency statistics were performed on each of the health care system 
characteristics (number of prescribers, number of dispensaries) for decedents with 
CACHES and the distributions reported as percentages.  A Mann-Whitney analysis was 
performed to compare the number of prescribers and dispensaries between the decedents’ 
with CACHES and decedents’ without CACHES.   
 
 
Protection of Human Subjects 
 
On August 30, 2011 the researcher contacted Dr. Amy McMaster Hawes, Chief 
Medical Examiner for Davidson County, requesting access to data contained in the 
Forensic Medical’s death charts.  Dr. McMaster Hawes granted entrée to the data on 
October 17, 2011, pending Institutional Review Board approval.  The researcher 
requested permission to conduct the study from the University of Tennessee Health 
Sciences Center (UTHSC) Institutional Review Board (IRB) on June 18, 2012.  Per the 
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IRB review of the proposal, the study met criteria for Exempt status under 45CFR46.102 
(f).  Specifically, the human subjects were deceased at the time of the study and subjects’ 
protected health information (PHI) would be kept confidential through the course of the 
study as well as in any subsequent published works stemming from this study.  The IRB 
granted final approval for the study on July 13, 2012.  The researcher sent an electronic 
copy of the approval letter to Dr. McMaster Hawes and Fran Wheatley prior to initiating 
data collection.  During the course of the study, all efforts were made to protect the 
confidentiality of the decedents’ data.   
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CHAPTER 4.    RESULTS 
 
 
This chapter reports the results of a retrospective, secondary analysis of data 
collected by Forensic Medical Management Services, PLC during the course of death 
scene investigations in Davidson County, Tennessee from January 1, 2011 - December 
31, 2011.  This chapter first presents a description of the study sample selection process 
(Figure 4-1).  This is followed by a descriptive analysis of the demographic 
characteristics of the subjects who expired at home with medications (n = 210) versus 
without medications (n = 80).  Next, the following five study aims are presented with the 
associated statistical analyses and discussion of results: 1) to describe the prevalence of 
CACHES found in decedents’ homes in Davidson County; 2) to examine the size and 
composition of the CACHES; 3) among decedents with medications in the home, to 
compare individual risk factors (gender, race, age, comorbid conditions) between those 
with CACHES and those without CACHES; 4) to describe the relationship between 
geographic location (Zip code) and the presence of CACHES in decedents’ homes; and 
5) among decedents with medications, to compare health care risk factors (number of 
prescribers and number of dispensers) between those with CACHES and those without 
CACHES.  Finally, a summarization of the study population and analysis results is 
provided.   
 
 
Final Study Sample 
 
The researcher selected the study sample based on the established inclusion and 
exclusion criteria (Figure 4-1).  First, the researcher excluded decedents who had expired 
outside of Davidson County (n = 1146).  Of the remaining decedents (n = 1400), 58 were 
excluded due to less than 18 years of age and an additional 691 subjects were excluded 
due to their deaths happening in a hospital.  Medical Examiner jurisdiction was waived 
for “home death” cases involving no evidence of trauma, drug overdose, homicide or 
suicide and manner of death was ruled “natural” by the decedent’s primary care provider 
(n = 86).  Ninety-nine non-residential deaths (decedent found in a hotel room, wooded 
area, river or lake, and in or near car) and eight deaths in which the decedent expired in a 
residence belonging to a friend, family member, or acquaintance were excluded.  The 
researcher also excluded cases in which decedents expired under Hospice care (n = 122) 
or were institutionalized in a long term care facility, prison, or jail cell (n = 44).  Finally, 
the Medical Examiner re-issued Death Certificates for two subjects due to a prior clerical 
error, but was not involved in investigation of these deaths.  Of the remaining decedents 
(n = 290), 210 expired in their homes with evidence of medications (currently in use 
and/or unused) in the home, while 80 subjects had no medications.   
 
 
Descriptive Statistics of Study Sample 
 
An analysis of the demographic characteristics of the decedents who expired at 
home with medications (n = 210) versus without medications (n = 80) was performed in  
 44 
 
 
 
Figure 4-1. Process of Excluding Subjects for Dissertation Study 
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two parts.  First, the two groups were compared to determine differences in gender, race, 
and age (Table 4-1).  Second, the decedents’ (n = 290) gender, race, and age were 
compared to the population of Davidson County in 2011.  An alpha level of 0.05 was 
adopted for this and all subsequent statistical tests.   
 
 
Decedents with versus without Medications 
 
Male decedents with medications in the home (n = 133, 63%) outnumbered 
female decedents (n =77, 37%).  The same gender difference was in evidence for those 
decedents without medications in the home with 53 (65%) being men and 27 (34%) being 
female.  Similar proportions of men and women were found in both groups with almost 
two-thirds of the group being comprised of men.  A Pearson’s Chi-squared analysis was 
performed to determine if males and females were distributed differently across the group 
with medications in the home versus no medications in the home.  The test failed to 
indicate a significant difference between the two groups, X2 (1) = 0.214, p = 0.643.  
 
Caucasian/Non-Hispanics made up the majority of decedents for both the 
medications (n = 168, 80%) and no medications (n = 59, 74%) groups.  The next largest 
racial group was African Americans (n = 41, 19% vs. n = 20, 25%).  Other minorities 
represented included one Hispanic decedent (1%) in the medications group and one Asian 
(1%) in the no medications group.  In light of the minimal number of Hispanic and Asian 
decedents, the decision was made to combine the African American, Hispanic and Asian 
decedents into one variable labeled non-Caucasian.  A Pearson’s Chi-squared analysis 
test failed to indicate a significant difference in racial distribution across the two groups 
(with medications and without), X2 (1) = 1.331, p = 0.249.   
 
Finally, both the decedents with medications and the decedents without 
medications had a normal distribution for the variable of age.  An independent two 
sample t-test (288) = -0.351, p = 0.726 showed no statistical difference between the two 
groups. 
 
 
Sample Demographics versus Davidson County Demographics 
 
Table 4-2 compares demographic data of the study sample to the demographic 
data for all persons greater than 18 years of age living in Davidson County.  A 
comparison of demographic characteristics of the sample shows an overrepresentation of 
males (63%) to females (37%) when compared to Davidson County (48% and 52%).  The 
study sample racial distribution follows a similar trend to Davidson County: 
Caucasians/Non-Hispanic (78% vs. 67%), African Americans (21% vs. 26%) and Other 
(1% vs. 7%).  Finally, the study sample has an underrepresentation of decedents ages 18-
44 (23%) in comparison to the Davidson County population (56%).  This trend reverses 
for the 45-64 year old group when comparing the sample (57%) versus Davidson County 
(30%) and also those in the 65+ age group (20% vs. 14%). 
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Table 4-1. Demographic Data for Subjects Who Died at Home with Medications 
in the Home versus Those without Medications in the Home (N = 290) 
 
 
  
 
Subject Characteristics 
Sample 
Home Death with 
Medications (N=210) 
n (%) 
Home Death without 
Medications (N=80) 
n (%) 
Gender   
  Female 77 (37%) 27 (34%) 
  Male 133 (63%) 
 
53 (66%) 
Race/Ethnicity   
  Caucasian (Non-Hispanic) 168 (80%) 59 (74%) 
  African American 41 (19%) 20 (25%) 
  Hispanic 1 (1%) 0 (0%) 
  Asian 0 (0%) 
 
1 (1%) 
Age Group   
  18-35 21 (10%) 14 (18%) 
  36-45 30 (14%) 5 (6%) 
  46-64 121 (58%) 41 (51%) 
  65+ 38 (18%) 
 
20 (25%) 
Mean Age (SD) 53.6 (13.7) 
 
54.3 (17.3) 
Median Age 54.0 
 
55.0 
Interquartile Range 17 20 
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Table 4-2. Demographic Data of Subjects versus Demographic Data for the 
Population of Davidson County  
 
 
aU.S. Census, 2005-2009. 
 
  
 
Subject Characteristic 
Sample 
Home Deaths  
(N=290) 
n (%) 
Davidson Countya  
(N=443,444) 
n (%) 
Gender   
  Female 77 (37%) 252,089 (52%) 
  Male 133 (63%) 
 
231,137 (48%) 
Race/Ethnicity   
  Caucasian (Non-Hispanic) 227(78%) 311,524 (67%) 
  African American 61 (21%) 121,914 (26%) 
  Other 2 (1%) 
 
30,488 (7%) 
Age Groups   
  18-44 66 (23%) 269,593 (56%) 
  45-64 166 (57%) 146,627 (30%) 
  65+ 58 (20%) 67,006 (14%) 
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Aim One 
 
Aim One: To describe the prevalence of CACHES found in decedents’ homes in 
Davidson County from January 1, 2011 through December 31, 2011.   
 
Of the 290 decedents, 210 had medications found in the home.  For 31 (15%) of 
these decedents with medication in the home, determination of CACHES was not 
possible because information on the medication’s dispense date was missing.  There were 
163 decedents with one or more bottles of unused medications as defined for this study 
(>7 days passed use by date).  The prevalence of CACHES in the home was calculated by 
dividing the number of decedents with CACHES (163) by the total sample size (290) and 
then multiplying by 100.  This resulted in a calculated prevalence of 56%.   
 
 
Aim Two 
 
Aim Two: To examine the size and composition of CACHES found in decedents’ 
homes in Davidson County from January 1, 2011 - December 31, 2011. 
 
Table 4-3 provides the frequency distribution of the number of bottles of unused 
medications among the 163 decedents with CACHES.  There were a total of 812 bottles 
of unused medications distributed among the 163 decedents.  The mean number of bottles 
of unused medications for those decedents with CACHES in the home (n=163) was M = 
5.0, SD ± 4.5.  Approximately half (53%) of the decedents had four or more bottles of 
unused medications.  The maximum number of bottles found in a decedent’s home was 
23.  The sum total of unused pills was 30,855.5.  This translated into a mean of M = 38.9, 
SD = ± 43.7 unused pills per decedent.  Of note, the researcher excluded medications in 
liquid, cream, or aerosolized form from these calculations, due to difficulty in accurately 
determining the remaining number of doses.   
 
Table 4-4 provides the frequency distribution of the classes of medications found 
in CACHES in decedents’ homes.  Medications are classified according to their class 
(system of action) and category (specific disease/symptom treatment focus).  Over 60% 
of the unused medications belonged to two major classes – those acting on the central 
nervous (CNS) system (34.7%) and the cardiovascular (CV) system (26.5%).  
Antihypertensives (n = 175, 21.5%), antidepressants (n = 69, 8.5%), anticonvulsants (n = 
50, 6.2%), antibiotics (n = 51, 6.3%), and antipsychotics (n = 41, 5.0%) were the five 
most common classes of all unused medications.  In addition, five commonly diverted 
classes (opioids, benzodiazepines, muscle relaxers, sedatives, and stimulants) comprised 
11.8 % (n = 96) of all CACHES.   
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Table 4-3. Number of Bottles of Medications Found among Decedents with 
CACHES (N = 812) 
 
Bottles of Unused 
Medications 
Frequency Percent Cumulative 
Percent 
1 40 24.5 24.5 
2 18 11.0 35.6 
3 18 11.0 46.6 
4 25 15.3 62.0 
5 7 4.3 66.3 
6 9 5.5 71.8 
7 9 5.5 77.3 
8 9 5.5 82.8 
9 8 4.9 87.7 
10 3 1.8 89.6 
11 1 0.6 90.2 
12 3 1.8 92.0 
13 4 2.5 94.5 
14 1 0.6 95.1 
15 0 0 95.1 
16 2 1.2 96.3 
17 1 0.6 96.9 
18 2 1.2 98.2 
19 1 0.6 98.8 
20 1 0.6 99.4 
21 0 0 99.4 
22 0 0 99.4 
23 1 0.6 100.0 
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Table 4-4. Frequency of Classes of Unused Medications among Decedents with 
CACHES (N=812 Medication Bottles) 
 
Class Category Frequency Percent Cumulative 
Percent 
Central 
Nervous 
System 
Alzheimer’s, anticonvulsant, 
antidepressant, antihistamine, 
antipsychotic, opiate, 
Parkinson’s, sedative, 
benzodiazepine, sedative, 
muscle relaxer, stimulant 
282 34.7 34.7 
Cardiovascular Antihypertensive, antiplatelet, 
cardiac inotropic, 
hemorrheologic, antilipid, anti-
angina 
215 26.5 61.2 
Dermatology Analgesic, corticosteroid 4 0.5 61.7 
Endocrine Androgen, antiosteoporosis, 
antithyroid, diabetes, estrogen, 
thyroid, Vitamin D 
50 6.2 67.9 
Eyes, Ears, 
Nose, Throat 
Antitussive, decongestant, 
mucolytic, glaucoma 
11 1.3 69.2 
Gastrointestinal Anticholinergic, antiemetic, 
antiflatulent, antiulcer, 
Chron’s, H2 Blocker, laxative, 
proton pump inhibitor, 
prokinetic 
54 6.6 75.8 
Genitourinary Anticholinergic, anti-
impotence, prostate, urinary 
tract 
22 2.7 78.5 
Hematology Anticoagulant, hematinic 8 1.0 79.5 
Infectious 
Disease 
Antibiotic, antifungal, 
antimalarial, antiretroviral, 
antiviral 
69 8.5 88 
Nutritional Electrolyte, phosphate, vitamin 30 3.7 91.7 
Pulmonary Bronchodilator 3 0.4 92.1 
Rheumatology Corticosteroid, DMARD, gout, 
NSAID 
59 7.3 99.4 
Cancer Anti-androgen 1 0.1 99.5 
Other Antabuse, muscle rub, phenol 
spray, unknown 
4 0.5 100 
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Aim Three 
 
Aim Three: Among decedents with medications in the home, to compare 
individual risk factors (gender, race, age, comorbid conditions) of those with CACHES to 
those without CACHES.   
 
 
Gender, Race, Age, and CACHES   
 
Table 4-5 provides a summary of the individual risk factors (gender, 
race/ethnicity, age) of decedents with and decedents without CACHES in the home.  A 
larger number of males than females were present in both the CACHES (n= 100 vs. 
n = 63) and no CACHES (n = 12 vs. n = 4) groups.  A Pearson’s Chi-squared analysis 
was performed to determine if males and females were distributed differently across 
CACHES versus no CACHES.  The test failed to indicate a significant difference, X2 (1) 
= 1.159, p = 0.282.  Caucasians/Non-Hispanic were the predominant race represented in 
both the CACHES (n = 129, 79%) and no CACHES (n = 12, 75%) groups.  Non-
Caucasian decedents made up the remaining sample population for both the CACHES 
(n = 34, 21%) and no CACHES groups (n =4, 25%).  There was no significant racial 
difference, X2 (1) = 0.149, p = 0.699 in the CACHES versus non CACHES groups. An 
independent t-test comparing the mean age for decedents with CACHES in the home 
(M = 55.5, SD ± 13.4) versus decedents without CACHES in the home (M = 46.3, SD ± 
11.6) was statistically significant (p = 0.009, t value = -2.64) with 95% CI (-16.08, -2.33). 
 
 
Comorbid Conditions and CACHES 
 
 Data on comorbid conditions were collected on all decedents with medications 
found in the home (n = 210).  Comorbid conditions were coded into 4 major categories: 
psychiatric (anxiety, depression, bipolar, schizophrenia), substance abuse (illicit or 
“street” drugs, alcohol, prescription drugs), cognitive disorder (dementia, mild cognitive 
impairment, post cerebral vascular accident), and other (all other chronic diagnoses).  A 
summary of the decedents’ total comorbid conditions and breakdown into specific 
categories follows (Table 4-6). 
 
 Approximately one-quarter of the 210 decedents had 0-2 (26%), 3-4 (26%), 5-7 
(24%), and 8-14 (23%) comorbid conditions.  Of the 210 decedents with medications: 99 
(47%) had at least one psychiatric diagnosis; 90 (43%) had a history of substance abuse, 
and; 27 (13%) had documented evidence of a cognitive disorder diagnosis.  The mean of 
the subjects’ comorbid conditions was M = 5.0, SD ± 3.2.  This sample was not normally 
distributed (Skewness = 0.69, SE = 0.17). 
 
 Table 4-7 provides a summary of the decedents’ total comorbid conditions and 
presence or absence of a psychiatric, substance abuse, or cognitive disorder diagnosis 
among decedents’ with CACHES (N = 163) and those without CACHES (N = 16).  The 
distribution of total comorbid conditions for the 179 subjects was not normal (Skewness  
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Table 4-5. Demographic Data of Decedents Who Died at Home with CACHES 
(N = 163) versus Those without CACHES (N = 16) 
 
 
aUnable to determine CACHES categorization of medication data (n = 31), these 
decedents were not included in summary demographic statistics. 
 
 
 
 
 
   
 
 
 
 
  
 
Decedent Characteristic 
Samplea 
Home Death with 
CACHES (N = 163) 
n (%) 
Home Death without 
CACHES (N = 16) 
n (%) 
Gender   
  Female 63 (39%) 4 (25%) 
  Male 100 (61%) 
 
12 (75%) 
Race/Ethnicity   
  Caucasian (Non-Hispanic) 129 (79%) 12 (75%) 
  Non-Caucasian (African 
  American, Hispanic, Asian) 
 
34 (21%) 4 (25%) 
Age Group 55.5 ± 13.4 46.3 ±11.6 
  18-35 12 (7%) 2 (13%) 
  36-45 21 (13%) 5 (31%) 
  46-64 97 (60%) 8 (50%) 
  65 + 33 (20%) 1 (6%) 
 53 
Table 4-6. Total Comorbid Conditions and Presence or Absence of Psychiatric, 
Substance Abuse, and Cognitive Disorder Diagnoses for Decedents with Medications 
(Currently in Use and Unused) in the Home (N = 210) 
 
  Decedent Characteristic Sample (N = 210) 
n (%) 
Sum of Comorbid Conditions  
  0-2 55 (26%) 
  3-4 55 (26%) 
  5-7 51 (24%) 
  8-14 49 (23%) 
Psychiatric  
  No 111 (53%) 
  Yes 99 (47%) 
Substance Abuse  
  No 120 (57%) 
  Yes 90 (43%) 
Cognitive Disorder   
  No 183 (87%) 
  Yes 27 (13%) 
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Table 4-7. Total Comorbid Conditions and Presence or Absence of Psychiatric, 
Substance Abuse, and Cognitive Disorder Diagnoses for Decedents with CACHES 
(N = 163) versus Those without CACHES (N = 16) in the Home 
 
 
Note. Thirty-one decedents were excluded from this sample due to missing “dispense by” 
data hindering the researcher’s ability to determine whether decedents were in the 
CACHES or No CACHES group. 
 
 
  
 
Decedent Characteristic 
Sample 
Home Death with 
CACHES (N = 163) 
n (%) 
Home Death without 
CACHES (N = 16) 
n (%) 
Sum of Comorbid Conditions   
  0-2 36 (22%) 5 (31%) 
  3-4 40 (25%) 5 (31%) 
  5-7 43 (26%) 4 (25%) 
  8-14 44 (27%) 2 (13%) 
Psychiatric   
  No 74 (45%) 15 (94%) 
  Yes 89 (55%) 1 (6%) 
Substance Abuse   
  No 97 (60%) 7 (44%) 
  Yes 66 (40%) 9 (56%) 
Cognitive Disorder   
  No 140 (86%) 14 (88%) 
  Yes 23 (14%) 2 (12%) 
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= 0.622, SE = 0.182).  A Mann-Whitney analysis of the median total comorbid conditions 
in decedents with CACHES versus those without CACHES was not statistically 
significant (U = 984, p = 0.104).  A Pearson’s Chi-squared analysis was performed to 
determine if a psychiatric, substance abuse, or cognitive disorder diagnosis was 
associated with the presence of CACHES in the home.  The test indicated a statistically 
significant association (X2 (1) = 13.6, p < 0.05) of CACHES in the home for those 
decedents with a psychiatric diagnosis.  However, there was no statistically significant 
association for decedents with a diagnosis of substance abuse (X2 (1) = 1.5, p = 0.223) or 
cognitive deficit (X2 (1) = 0.03, p = 0.859). 
 
 
Aim Four 
 
Aim Four: To describe the relationship between geographic location (Zip code) 
and CACHES. 
 
 Table 4-8 provides the frequency distribution of CACHES in Davidson County.  
CACHES were found in 27 of 35 Davidson County Zip codes.  Over half (50.3%) of 
CACHES were distributed among 6 Zip codes: 37221 (4.9%), 37013 (5.5%), 37115 
(7.9%), 37206 (8.5%), 37207 (9.1%), and 37211 (14%). 
 
 
Aim Five 
 
 Aim Five: Among decedents with medications, to compare health care system risk 
factors (number of prescribers, number of dispensaries) between those with CACHES to 
those without CACHES.  
 
 Tables 4-9 and 4-10 display the frequency distribution of the number of 
prescribers used by decedents with (Table 4-9) and without (Table 4-10) CACHES in 
the home. 
 
 Table 4-11 provides a comparison of the mean, median, and standard deviation of 
the number of prescribers used by decedents with and without CACHES in the home.  
According to the analysis (Table 4-11), the CACHES group had a skewed distribution of 
prescribers (Skewness = 1.1, SE = 0.2), as did the no CACHES group (Skewness = 1.7, 
SE = 0.6) group.  A Mann-Whitney analysis of the two group medians showed a 
statistically significant difference (U = 433.5, p < 0.05) between the two groups.  The 
CACHES group used a significantly higher number of prescribers than the decedents 
without CACHES. 
 
 Tables 4-12 and 4-13 display the frequency distribution of the number of 
dispensaries used by decedents with (Table 4-12) and without (Table 4-13) CACHES in 
the home. 
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Table 4-8. Frequency Table of Number of CACHES per Zip Code (N = 163) 
 
Zip Code Frequency Percent Cumulative Percent 
37080 1 .6 .6 
37116 1 .6 1.2 
37212 1 .6 1.8 
37220 1 .6 2.5 
37027 2 1.2 3.7 
37215 2 1.2 4.9 
37219 2 1.2 6.1 
37189 3 1.8 8.0 
37204 3 1.8 9.8 
37216 3 1.8 11.7 
37072 4 2.5 14.1 
37138 4 2.5 16.6 
37205 4 2.5 19.0 
37217 4 2.5 21.5 
37218 4 2.5 23.9 
37076 7 4.3 28.2 
37203 7 4.3 32.5 
37208 7 4.3 36.8 
37209 7 4.3 41.1 
37210 7 4.3 45.4 
37214 7 4.3 49.7 
37221 8 4.9 54.6 
37013 9 5.5 60.1 
37115 13 7.9 68.1 
37206 14 8.5 76.7 
37207 15 9.1 85.9 
37211 23 14.0 100.0 
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Table 4-9. Frequency Distribution of the Number of Prescribers Used by 
Decedents with CACHES in the Home (N = 161) 
 
Number of 
Prescribers 
Frequency Percent Cumulative 
Percent 
1 41 25.5 25.5 
2 43 26.7 52.2 
3 30 18.6 70.8 
4 20 12.4 83.2 
5 11 6.8 90.1 
6 8 5.0 95.0 
7 4 2.5 97.5 
8 3 1.9 99.4 
9 1 0.6 100.0 
 
Note.  Prescriber information unavailable for 2 of the original 163 decedents with 
CACHES in the home. 
 
 
 
Table 4-10. Frequency Distribution of the Number of Prescribers Used by 
Decedents without CACHES in the Home (N = 15) 
 
Number of 
Prescribers 
Frequency Percent Cumulative 
Percent 
1 12 80.0 80.0 
2 3 20.0 100.0 
 
Note.  Prescriber information unavailable for 1 of the original 16 decedents without 
CACHES in the home. 
 
 
 
Table 4-11. Descriptive Statistics of the Number of Prescribers Used by Decedents 
with CACHES and without CACHES (N = 176) 
 
Groups Decedents Mean Median SD Min, 
Max 
Skewness Std. 
Error 
Shapiro-
Wilk 
CACHES 161 2.9 2.0 ±1.8 1,9 1.1 0.2 0.0 
Without 
CACHES 15 1.2 1.0 ±0.4 1,2 1.7 0.6 0.0 
 
Note.  Prescriber data unavailable for (n = 3) decedents. 
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Table 4-12. Frequency Distribution of the Number of Dispensaries Used by 
Decedents with CACHES in the Home (N = 162) 
 
Number of 
Dispensaries 
Frequency Percent Cumulative 
Percent 
1 81 50.0 50.0 
2 43 26.5 76.5 
3 25 15.4 92.0 
4 6 3.7 95.7 
5 6 3.7 99.4 
6 1 0.6 100.0 
 
Note.  Dispensary information missing for 1 of the original 163 decedents with CACHES 
in the home. 
 
 
 
Table 4-13. Frequency Distribution of the Number of Dispensaries Used by 
Decedents without CACHES in the Home (N = 15) 
 
Number of 
Dispensaries 
Frequency Percent Cumulative 
Percent 
1 12 80.0 80.0 
2 3 20.0 100.0 
 
Note.  Dispensary information missing for 1 of the original 16 decedents without 
CACHES in the home. 
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Table 4-14 displays the mean, median, and standard deviation of the number of 
dispensaries used by decedents with CACHES and without CACHES in the home. 
 
An analysis of the distribution of the two groups (CACHES and without 
CACHES) based on the number of dispensers also showed a non-normal, skewed 
distribution (Table 4-14).  A Mann-Whitney analysis of the two group medians showed a 
statistically significant difference (U = 793.5, p = 0.015) with the CACHES group using a 
higher number of dispensers than the decedents without CACHES in the home. 
 
 In summary, analysis of the Medical Examiner data showed no statistical 
differences in gender, race, or age when comparing decedents with medications (used and 
unused) in the home and those decedents with no medications in the home.  The ME 
study sample is majority male, Caucasian/Non-Hispanic, and older than the general 
Davidson County population.  CACHES are a prevalent issue with more than half of the 
study sample having four or more bottles of unused medications in the home with a mean 
of 5.0 (SD ± 4.5) bottles and 38.9 (SD ± 43.7) unused pills per decedent.  On average, 
60% of these unused medications come from two major classes of medications – those 
affecting the central nervous system and the cardiovascular system. There are several 
significant differences between the decedents with CACHES and those without CACHES 
in the home.  The CACHES group is significantly older, has a higher likelihood of having 
a psychiatric diagnosis, sees more prescribers and uses more dispensaries than the 
decedents without CACHES in the home.  The analyses did not support a statistical 
difference between the two groups with regards to gender, race/ethnicity, or total number 
of comorbid conditions.  There were insufficient data to perform an analyses on the 
relationship between geographical location (Zip code) and CACHES. 
 
 
Table 4-14. Descriptive Statistics of the Number of Dispensaries Used by 
Decedents with CACHES and without CACHES (N = 177) 
 
Groups Decedents Mean Median SD Min, 
Max 
Skewness Std. 
Error 
Shapiro-
Wilk 
CACHES 162 1.9 1.5 ±1.1 1,6 1.4 0.2 0.0 
Without 
CACHES 15 1.2 1.0 ±0.4 1,2 1.7 0.6 0.0 
 
Note.  Dispensary data unavailable for (n = 2) decedents. 
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CHAPTER 5.    DISCUSSION 
 
 
The CACHES pilot study was a retrospective, secondary analysis of data 
collected by Forensic Medical’s Medicolegal Death Investigators and Medical Examiners 
Board Certified Pathologists during the investigation of 210 home deaths occurring in 
Davidson County, Tennessee between January 1, 2011 through December 31, 2011.  This 
chapter provides an in depth discussion of the study results in the context of the 
CACHES conceptual framework and the supporting literature.  First, will be a discussion 
about differences between the study sample and Davidson County demographics (gender, 
race, age) and potential reasons for these differences.  Second, this chapter will compare 
and contrast the prevalence rate, size and composition of CACHES to those found in 
previous studies.  Furthermore, the chapter will address the relationship between 
individual risk factors (gender, race, age, comorbid conditions, geographical location) 
and stockpiling of unused medications in the home.  The researcher also will discuss the 
relationship between health care risk factors (multiple prescribers, multiple dispensaries) 
and CACHES.  Finally, this chapter will discuss the limitations of this pilot study, 
implications of the study findings for practice, policy, and future research. 
 
 
CACHES Sample versus Davidson County Population 
 
The study population displayed several demographic differences when compared 
to the general population of Davidson County.  The CACHES study population was 
majority male, Caucasian/Non-Hispanic, and over half of the sample was in the age range 
of 44-64 years of age.  This section addresses the factors influencing the gender, race, and 
age distribution of the CACHES sample.   
 
 
Gender 
 
There is an overrepresentation of male decedents in the CACHES study sample 
(63%) in contrast to Davidson County (48%) (Tennessee Department of Health, 2011).  
As mentioned previously, the Medical Examiner accepts jurisdiction in cases of violent 
(homicide), traumatic (suicide, accident), and/or unexpected deaths.  A review of law 
enforcement statistics for Davidson County identify males as being at higher risk for a 
violent or traumatic death in comparison to their female counterparts.  The 2011 
Metropolitan Nashville Police Department (MNPD) homicide data report indicated 303 
males died as a result of homicide versus 95 females (Metro Nashville Police 
Department, 2011).  This trend is also seen in the most recent data available (2007) from 
the Tennessee Department of Health’s analysis of age-adjusted homicide rate for males 
(21.1) versus females (4.2).  Rogers et al. (2013) analysis of Davidson County 2010 data 
for suicides also show males outnumbering females in age-adjusted suicide rates (19.1 
versus 3.4).  In Davidson County, men are at higher risk to die from a violent (homicide) 
or traumatic (suicide) death than their female counterparts.  These data provide an 
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explanation for the disparity of gender distribution seen in the Medical Examiner data 
when compared to the gender distribution of the population of Davidson County. 
 
 
Race 
 
The distribution of race in the study population also varied when compared to 
Davidson County statistics (2011): Caucasians/Non-Hispanic (78% vs. 67%), African 
Americans (21% vs. 26%), and Other (1% vs. 7%).  African Americans, Hispanics, and 
Asians are underrepresented in the CACHES sample.  Nashville’s Metro Department of 
Health’s analysis of “Age-adjusted Mortality Rated for 10 Overall Leading Causes of 
Death Ranked by Frequency for Racial/Ethnic and Sex Groups, Davidson County, TN 
2010” provide a potential explanation for this mismatch.  In 2010, African Americans 
had a higher mortality rate than Caucasian/Non-Hispanics and Hispanics in 5 out of the 
10 leading causes of death (Rogers et al., 2013).  These five categories include: heart 
disease, cancer, stroke, diabetes, and Alzheimer’s Disease.  Furthermore, the Department 
of Health’s age-adjusted mortality rates (2013) show that Hispanics died from 
complications related to Nephritis/Nephrotic Syndrome/Nephrosis at a rate 4 times (40.3) 
as often as Caucasians (9.5) and almost 2 times as often as African Americans (25.4).  All 
six of these categories fall under the definition of death due to natural causes.  Procedural 
rules dictate Forensic Medical’s MLDIs make contact with the decedent’s PCP (if this 
information is made available) to obtain a medical history prior to accepting jurisdiction 
of a new death investigation.  If the PCP indicates the decedent likely died from natural 
causes, agrees to sign the Certificate of Death, and on-scene law enforcement rule out 
signs of trauma, homicide and/or a suspicious death, then ME jurisdiction is waived.  
Law enforcement and the ME release the decedent’s body to be transferred directly to the 
funeral home without further on scene investigations.  Per the Metro Department of 
Health’s statistics (2013), African Americans and Hispanics are more likely to die of 
natural causes when compared to their Caucasian/Non-Hispanic counterparts.  This then 
contributes to the underrepresentation of African American and Hispanic subjects in the 
ME data when compared to the general Davidson County population.  
 
This race disparity is further heightened by an overrepresentation of 
Caucasians/Non-Hispanics in the CACHES data.  Again turning to the Metro Health 
Department “Causes of Death” data, in Davidson County Caucasians/Non-Hispanics 
have a higher age-adjusted mortality rate secondary to accidents (59.5) and suicides 
(14.4) than their African American (49.4 and 3.9) and Hispanic (24.7 and 1.8) 
counterparts (Rogers et al., 2013).  According to the TN legal code and NAME 
guidelines, deaths related to accidents and suicide automatically are accepted under the 
ME’s jurisdiction.  In conclusion, the overrepresentation of Caucasian/Non-Hispanics 
and underrepresentation of African Americans, Hispanics and Asians in the CACHES 
sample reflects the patterns seen in the Davidson County statistics on race and likely 
cause (disease vs. trauma) and nature of  (natural vs. accident/violent) death. 
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Age 
 
The age of the CACHES sample population skewed older when compared to the 
larger Davidson County population.  Decedents in the 44-64 years old category 
represented over half (57%) of the CACHES study sample, followed by (20%) in the 65+ 
age category.  In addition, the study sample has an underrepresentation of subjects ages 
18-44 (23%) in comparison to the Davidson County population (56%).  These findings 
are not surprising when considering the positive relationship between increasing age and 
increased mortality rates and the source of the CACHES data set.  The Tennessee Deaths 
2011 report clearly demonstrates this relationship people with a rate of 189.9 
deaths/100,000 for people ages 25-44 versus 9,629 deaths/100,000 for people ages 65-74 
(Office of Health Statistics, 2011).  
 
It is important to note in the CACHES sample the largest percentage of decedents 
were those in the 44-64 year old category.  Revisiting the list of leading causes of death 
in TN, the underrepresentation of decedents 65 and older likely is explained by two 
factors.  First, subjects 65 years and older are more likely to die from natural causes than 
their younger counterparts, as is reflected in the Davidson County 2007-2009 death data 
(Tennessee Department of Health, 2011).  In these cases, the ME would waive 
jurisdiction, which would lead to an under sampling of decedents ages 65+ years of age.  
In addition, when comparing death related to assault (homicide) or intentional self-harm 
(suicide), the TN Department of Health statistics (2011)provide a clear picture of 
increased risk of death secondary to assault (homicide) and self-inflicted harm (suicide) 
when comparing younger adults (35-64) to older adults (65+).  Suspected homicides and 
suicides are automatically accepted under the jurisdiction of the ME’s office, thus 
weighting the ME sample towards subjects in the 44-64 year age range.  
 
In summary, due to the legal jurisdiction requirements of ME involvement in the 
investigation of traumatic, violent, and suspicious deaths, the ME data sample is skewed 
towards those populations at risk for homicide, suicide, and/or accidental deaths.  This is 
reflected by the overrepresentation of 44-64 year old, Caucasian/Non-Hispanic males in 
the CACHES data set.  As such, the results of the CACHES pilot study have limited 
generalizability when applied to the larger Davidson County population. 
 
 
Medications in the Home 
 
The CACHES study examines the prevalence, size, and composition of unused 
medications found in the homes of decedents by the MLDIs during the course of death 
scene investigations.  Out of the final study sample (n = 290), 72% (n = 210) of the 
decedents had at least one or more containers of currently-in-use and/or unused 
medications in the home at the time of their death.  While not a direct comparison, the 
Institute of Medicine’s “Quality Chasm” series reported 80% of the sampled US 
population using at least one prescription or OTC medication in the past week (Institute 
of Medicine of the National Academies, 2007).  In contrast, the U.S. Department of 
Health and Human Services examination of trends from 2005-2008 in health statistics 
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reported 47.2% of non-institutionalized (community-dwelling) individual’s being on at 
least one prescription medication in the last 30 days (National Center for Health 
Statistics, 2011).  The CACHES results fall between these two national trends and 
highlight the fact that the majority of decedents had at least one medication in the home 
at the time of their death.  A further parsing of the CACHES data set reveals a sum 
number of 1770 medications (currently-in-use and unused) found during the course of 
death scene investigations.  This averages to 6.1 medications per decedent.  This study 
finding is not unexpected when placed in the context of Tennessee’s 17.6 prescriptions 
per capita rate (Kaiser Family Foundation, 2011b).  
 
Of those decedents’ with medications in the home, 56% of the decedents had a 
CACHE of least one or more containers of unused medications (> 7 days past “use by” 
date).  There are a handful of existing studies involving the direct survey of medications 
found in the community-dwelling adult’s home.  However, a comparison of the CACHES 
study findings to these existing studies is complicated by the following differences: 
variations in study population age and geographical location, differing definitions of what 
qualifies as “unused” medications, and origination of the data.  This next section 
compares the CACHES results to the existing studies, discusses these differences, and 
provides a final explanation as to the significance of the CACHES findings.  In addition, 
the limitations of the CACHES medication data are discussed and the impact of these 
limitations on the final calculations of prevalence rate, size and composition.   
 
 
Comparing Prevalence 
 
 
 Differences in study population.  Five of the nine comparison studies restricted 
sampling to an older adult population (≥ 65 years of age) with the majority having a mean 
age 70 years of age or older (Barat et al., 2000; Der, Rubenstein, & Choy, 1997; Morgan, 
2001; Torrible & Hogan, 1997; Wasserfallen et al., 2003).  The prevalence of unused 
medications for each of these studies were: 17.7% (Barat et al., 2000), 35% (Der et al., 
1997), 35.7% (Wasserfallen et al., 2003), 51.5% (Morgan, 2001), and 76% (Torrible & 
Hogan, 1997).  In contrast, the CACHES study population included subjects 18 years of 
age and older with a mean age of 53.8 (SD ± 14.7 years.  The four remaining comparison 
studies had similar study population age ranges (18 and older) with a trending of >50% of 
their population being 50+ years old (Bolle et al., 2008; Seehusen & Edwards, 2006; Shin 
et al., 2009; Sorensen et al., 2005).  The reported prevalence of unused medications for 
these studies were: 18.5% (Shin et al., 2009), 21% (Bolle et al., 2008), 21.1% (Sorensen 
et al., 2005), and 56.4% (Seehusen & Edwards, 2006).  When comparing these studies, 
the inclusion of younger subjects (who would be less likely to need or buy prescription 
medications) in the CACHES study likely accounts for the slightly lower prevalence rate.  
However, the difference in study subjects’ ages does not, by itself, provide sufficient 
explanation for the variation of prevalence rates.  For example, Seehusen and Edwards 
report (2006) the second highest prevalence rate (56.4%) of all studies, but had an equal 
distribution of subjects ages 18-49 (48.2%) and 50+ (51.8%) .  Additional factors, such as 
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geographic location and source of the data contribute to the differences in prevalence 
rates.  These differences will be addressed next. 
 
 
Differences in geographical location.  Six out of the nine comparison studies on 
unused medication prevalence were done in countries outside of the U.S. (Barat et al., 
2000; Bolle et al., 2008; Shin et al., 2009; Sorensen et al., 2005; Torrible & Hogan, 1997; 
Wasserfallen et al., 2003).  This is potentially significant when considering the U.S. 
population, on average, consumes more prescription medications than any of the other 
countries (Australia, Belgium, Canada, Denmark, South Korea, and Switzerland) 
represented in these comparison studies (Peterson & Burton, 2007).  More prescriptions 
per person increase the likelihood of unused medications in the home and ultimately 
would increase the prevalence rate.  Two out of the three highest prevalence rates come 
from U.S. studies (Morgan, 2001; Seehusen & Edwards, 2006) with the CACHES 
prevalence rate coming a close third.  One U.S. study (Der et al., 1997) had an outlier 
lower prevalence rate of 35%.  However, these investigators used one of the most 
restrictive definitions of unused medications limiting their data collection to those 
medications > 1 year past the dispensed date.  
 
In 2011, Tennessee had the third highest number of prescriptions per capita in the 
U.S. (Kaiser Family Foundation, 2011b).  This begs the question as to why the CACHES 
prevalence rate was not equal to or higher than the two other US studies, which took 
place in New Hampshire (Morgan, 2001) and Washington State (Seehusen & Edwards, 
2006).  This difference is likely explained by the nature of the ME data set.  As 
mentioned previously, the ME waives jurisdiction in cases of decedents determined to 
have died of natural causes (“expected deaths”).  Had these decedents been included in 
the data set, it is likely they would have increased the prevalence rate, as they would have 
been taking medications to manage their comorbid conditions. 
 
 
Defining “unused”.  The comparison of prevalence rates is further complicated 
due to there being little consensus between studies regarding what constitutes an unused 
medication.  Across the studies, definitions of unused medications included: “expired” 
medications as per the expiration date on the bottle label or >1 year past dispense date 
(Bolle et al., 2008; Der et al., 1997; Seehusen & Edwards, 2006; Sorensen et al., 2005); 
medications that were “discontinued” or no longer in use in the past month, but not 
expired (Barat et al., 2000; Torrible & Hogan, 1997; Wasserfallen et al., 2003); “wasted” 
medications prescribed within last year, but the participant indicated he/she had no 
intention to use the medication and expired medications (Morgan, 2001), and; “surplus” 
medications – which were not clearly defined by the researchers (Shin et al., 2009).  The 
CACHES study definition of unused medications most closely aligns with those used by 
Morgan, including both expired and unused medications (discontinued by provider or the 
decedent). 
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Differences in data sources.  All nine of the comparison studies conducted face-
to-face interviews, surveys, and/or made direct observations of the medications in the 
home setting with clarification of medication status (currently in use, not in use, expired) 
confirmed by the subject.  In contrast, the CACHES study involved a secondary analysis 
of medication data collected during death scene investigations.  Out of the 1770 
medication entries in the ME dataset, 373 (21.1%) lacked a “dispensed by” date.  Per 
discussions with Fran Wheatley (Lead Administrator), this is not uncommon as 
medications often are found on scene stored in weekly pill boxes and unmarked 
containers or loose in the vicinity of and/or on the decedent’s body.  These missing data 
made it impossible to calculate a “used by” date for these 373 medication entries, which 
hindered the determination of whether or not the medications were in current use or 
unused at the time of death.  As a result, these medications were excluded from the final 
CACHES prevalence rate.  Therefore, the CACHES study 56% prevalence rate is likely 
an underestimation of the overall prevalence of unused medications.  This then places the 
CACHES prevalence rate in line with the studies prevalence rates seen in other U.S. 
studies. 
 
 
Comparing Size 
 
 To facilitate a comparison of the size of the CACHES with prior studies, the 
discussion will define “size” both in terms of the number of bottles of unused 
medications and also the number of unused pills.  In the CACHES study, the mean 
number of unused bottles of medications in the home was 5.0 (SD ± 4.5).  Fifty-three 
percent of decedents had four or more bottles of unused medications in the home.  Ten 
percent had 10 or more bottles of unused medications stored in the home with one subject 
having a maximum of 23 bottles. 
 
 
Direct comparison.  Three studies (Der et al., 1997; Torrible & Hogan, 1997; 
Wasserfallen et al., 2003) reported the number of bottles of unused medications per 
subject.  Torrible and Hogan(1997) found subjects had, on average, 2 bottles of unused 
medications stored in the home .  However, Torrible and Hogan limited their data 
collection to prescription medications only, whereas the CACHES study includes both 
prescription and OTC medications.  Der et al.(1997) reported a similar finding to Torrible 
and Hogan, with each subject averaging 1.9 bottles of expired medications in the home .  
These researchers defined unused medications as those medications > 1 year past 
expiration date, thereby excluding any unused medications in the home that had been 
discontinued within the past 12 months.  As a result, a substantial number of bottles of 
unused medications could have been excluded from the final count.  In comparison, the 
CACHES study included unused medications that fell within the 12 month window.  
Therefore, it is not unexpected the CACHES average bottle count per subject was higher 
than Der et al.’s findings.  Wasserfallen et al. (2003) reported an average of 3.7 bottles of 
discontinued medications per subject .  Similar to the CACHES study, Wasserfallen et 
al.(2003) included both prescription and OTC medications in this data set.  However, the 
researchers excluded 354 (17.3%) bottles of medications from the calculations due to the 
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subject’s being unable to vocalize the indication for use, frequency of use, and/or any 
information regarding the medication (Wasserfallen et al., 2003).  Therefore, it is possible 
the average number of bottles of unused medications per subject was, in fact, higher for 
Wasserfallen et al. 
 
 
Indirect comparison.  Four of the nine studies do not provide direct comparisons 
to the CACHES estimation of size.  At issue is the type of data collected (Barat et al., 
2000; Bolle et al., 2008) and how it was reported (Seehusen & Edwards, 2006; Sorensen 
et al., 2005).  Barat et al. (2000) and Bolle et al. (2008) included both the subject’s and 
the subject’s spouse’s medications in the count of unused medications in the home.  Barat 
et al. (2000) reported 1.3 bottles per household  and Bolle et al. (2008) an average of 6.5 
bottles per subject.  For the Medical Examiner data, legal procedures dictate the MLDIs 
limit on-scene medication collection to those medications found in the decedent’s name 
only.  In specific cases if the MLDIs have a high suspicion the decedent’s death was 
secondary to the consumption of another household member’s medication, then this 
person’s medications may be collected as evidence.  However, this 2011 data set included 
only one such case out of the 210.  Seehusen and Edwards(2006) reported the number of 
unused medication bottles as ranges rather than an overall average number of bottles per 
subject.  Forty-eight percent of their subjects had 1-5 bottles of unused medications in the 
home followed by 6.4% having 6-10 bottles, 1.3% having 11-25, and 0.7% > 25 
(Seehusen & Edwards, 2006).  Sorensen et al. (2005) do not directly report the number of 
unused bottles or pills in their study findings.  Instead, they report on average the subjects 
were taking 9.9 medications, but had a total of 14.7 medications in the home.  The 
researchers do not explicitly state if the 4.8 difference includes PRN, expired, and/or 
discontinued medications.  The divergent nature of the data sets (Barat et al., 2000; Bolle 
et al., 2008) and reporting of the results (Seehusen & Edwards, 2006; Sorensen et al., 
2005) preclude making a direct comparison to the CACHES study findings. 
 
Finally, Morgan’s study (2001) reported the total number of wasted pills (n = 
2078) with an average of 31.5 wasted pills per participant. Morgan (2001) also excluded 
32 subjects who had no wasted pills.  Of the 163 decedents with CACHES, there were a 
total of n = 794 separate medication entries with a sum of n = 30,855.5 unused pills.  This 
translated into a mean of 38.9 (SD ± 43.7) pills per decedent.  Of note, the researcher 
excluded medications in liquid, cream, or aerosolized form from these calculations, due 
to difficulty in accurately determining the remaining number of doses.  As such, this 
means the average number of unused pills (doses) per decedent was likely higher than 
38.9.  
 
In conclusion, in the CACHES study the size of the unused medication stockpiles 
was larger than those found in prior studies.  This difference is even more striking when 
taking into consideration 21% of the CACHES medication information was excluded 
from the calculation due to missing “dispensed by” dates.  As with the high prevalence of 
CACHES in the homes, it is likely a combination of factors contributing to the larger size 
of the CACHES, including: geographical location (Tennessee has one of the highest 
prescription/capita rates in the country), sample age (older adults use more medications), 
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the use of a broader definition of unused medications (> 7 days past use-by-date), and the 
inclusion of both prescription and OTC medications in the sample. 
 
 
Composition 
 
The CACHES study assigned each unused medication a category based on both 
the system of action (cardiovascular, central nervous system, infectious disease, etc…) as 
well as the disease-specific medication categories (hypertension, hyperlipidemia, 
antidepressants, etc…).  Sixty-one percent of the unused medications belonged to two 
major classes – those acting on the central nervous (CNS) system (34.7%) and the 
cardiovascular (CV) system (26.5%).  These findings are similar to those in other studies 
of unused medications in the home (Barat et al., 2000; Linjakumpu et al., 2002; Torrible 
& Hogan, 1997; Wasserfallen et al., 2003) or returned to pharmacies for disposal (Bolle 
et al., 2008; Braund, Gn, et al., 2009; Cameron, 1996; Coma et al., 2008; Garey et al., 
2004; James et al., 2009; Langley et al., 2005).  Five of the most commonly diverted 
classes of medications (Manchikanti & Singh, 2008) including, opioids, benzodiazepines, 
muscle relaxers, sedatives, and stimulants, comprised 11.8% of all unused medications 
found in the homes of decedents.  Finally, unused infectious disease (ID) medications 
(antibiotics, antivirals, and antimalarial) were 8.7% of all unused medications. 
 
CV and CNS medications are two of the most frequently prescribed classes of 
prescription and OTC medications in both the US (Bartholow, 2012; Raofi & Schappert, 
2006) and outside the U.S. (Barat et al., 2000; Braund, Gn, et al., 2009; Linjakumpu et 
al., 2002).  Therefore, it is not surprising the CACHES study found these two categories 
of medications comprised the largest portion of unused medications in decedents’ homes.  
Of interest is the low number of unused controlled substances, when compared to the CV 
and non-controlled CNS medications.  There are three factors influencing this finding.  
First, 15.0% of the recorded controlled substances had no dispensed by date and/or were 
missing dose frequency information.  Therefore, the researcher could not make a 
determination of whether the remaining medications were currently in use or unused and 
therefore they were not included in the CACHES calculations.  Second, of the 166 
controlled substances calculated as having no unused doses (i.e. not defined as 
CACHES), 38.6% of these were due to over compliance (subject took more than the 
prescribed dosage).  Third, per discussions with Lead Administrator F. Wheatley 
(personal communication, March 28, 2013) it is not an uncommon occurrence for family 
members, friends, roommates, or other witnesses at the death scene to divert the 
decedent’s controlled substances prior to law enforcement or the MLDIs arrival on scene.  
This issue of diverted controlled substances from the death scene was captured in several 
of the reviewed cases – either in the Investigator Notes or in the Police Report.  These 
oral and written reports support the CACHES conceptual framework, which draws a 
direct relationship between unused controlled substances in the home and the diversion of 
these medications by friends and family members. 
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Individual Risk Factors 
 
 The CACHES model proposes specific characteristics of the individual (gender, 
race, age, and comorbid conditions) place him/her at risk for having CACHES in the 
home.  The model predicts female gender, Caucasian/Non-Hispanic race, advanced age 
(≥ 65 years of age), and having multiple comorbid conditions as placing the individual at 
highest risk for stockpiling unused medications in the home.  This pilot study attempts to 
explore the relationship of these risk factors and CACHES through an examination of the 
ME data.  This next section discusses the study findings and whether or not the findings 
support the CACHES model.   
 
 
Gender.  The CACHES model proposes female gender places the individual at 
increased risk for the accumulation of unused and expired medications in the home.  This 
assertion was based on previous studies demonstrating women are more likely than men 
to access medical care including prescription medications (Kaiser Family Foundation, 
2010c, 2011a).  Analysis of the Medical Examiner data showed no significant 
relationship between gender and the presences of CACHES.  There are several potential 
explanations for this finding.  As previously discussed, the study sample was skewed 
with men representing 63% of the population.  In comparison, the 2010 Census of 
Davidson County found men to make up 48% of the total population (Division of Health 
Statstics, 2010).  
 
One additional complicating factor is the influence of gender on adherence.  
Adherence studies have found women to be more likely to follow a prescribed 
medication regimen than their male counterparts (Fine et al., 2009).  These findings 
might suggest female gender could be both a protective and a risk factor for CACHES.  
Finally, this pilot study had a small sample size, which contributes to the difficulty of 
determining the relationship between CACHES and gender.  
 
 
Race.  Analysis of the CACHES data showed no significant relationship between 
race and risk for CACHES.  The researcher proposes these findings are likely due to two 
complicating factors.  First, as noted earlier, the Medical Examiner data set heavily 
skewed towards Caucasian/Non-Hispanic verses African Americans and Hispanics due to 
the nature of death (traumatic/violent vs. natural causes).  Second, African Americans 
and Hispanics are less likely to have access to and utilize health care – including 
prescription medications (Adams et al., 2013; Gellad et al., 2007; McClelland et al., 
2013).  Third multiple studies report African American and Hispanic patients are less 
adherent to prescribed medication regimens (Benner et al., 2002; Bosworth et al., 2008; 
Rolnick, Pawloski, Hedblom, Asche, & Bruzek, 2013; Siegel et al., 2007); however, 
additional research suggests this is a factor of socioeconomic status rather than race alone 
(Adams et al., 2013; Gellad et al., 2007; Goldman et al., 2007; McClelland et al., 2013; 
Rolnick et al., 2013; Turner et al., 2009).  The ME data do not provide information on the 
decedent’s socioeconomic status.  As a result, the researcher was not able to further 
explore the relationship between CACHES, race, adherence, and socioeconomic status. 
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Age.  The CACHES model posits advanced age (≥ 65 years of age) places the 
individual at higher risk for unused medications in the home.  Analysis of the study data 
showed a significant relationship between older age and having CACHES in the home.  
Of interest, the mean age for decedents’ with CACHES was 55.5 (SD ± 13.4) years old.  
While the standard deviation places the ME study sample within the CACHES proposed 
± 65 years old margin, the CACHES group mean age is approximately 10 years younger 
than predicted.  As previously discussed, the age group 45-64 was the largest segment 
(57%) of the CACHES study population with the ≥ 65 year old being the next largest 
group (20%).  This discrepancy was likely due to an under sampling of decedent’s ≥ 65 
in the ME data.  This under sampling was the result of the following factors: 1) subjects ≥ 
65 years of age are at lower risk for death secondary to violence (suicide, homicide) than 
their counterparts in the 45-64 age range; and, 2) decedents ≥ 65 years of age are at an 
increased likelihood to have died secondary to natural causes and therefore ME 
jurisdiction was waived. 
 
 
Comorbid conditions.  The CACHES model identifies having comorbid 
conditions as increasing the individual’s risk for accumulating unused medications in the 
home.  An analysis of the ME data did not support this relationship.  Again, the 
explanation of this finding likely lies within the nature of the ME data.  Decedents with a 
higher number of comorbid conditions would be at higher risk for a death secondary to 
natural causes.  This, in turn, would have eliminated the need for ME involvement in the 
investigation of the decedent’s death – leading to an under sampling of these decedents.   
 
The ME data did reveal a significant relationship between having a diagnosed 
psychiatric disorder and the presence of unused medications in the home.  Previous 
research suggests patients with psychiatric disorders are less adherent to prescribed 
medication regimens than those without a psychiatric disorder (Hansen, Maciejewski, 
Yu-Isenberg, & Farley, 2012; Lacro, Dunn, Dolder, Leckband, & Jeste, 2002; Rolnick et 
al., 2013).  This behavior of nonadherence would increase the risk of the accumulation of 
unused medications in the home.  
 
This pilot study explores the relationship between gender, race, age, and comorbid 
conditions and the presence of CACHES in the home.  The study findings support 
advanced age placing the individual at risk for the accumulation of unused medications in 
the home.  Furthermore, having a psychiatric condition also appears to increase this risk.  
More research needs to be done to tease out the effect of gender, race, and comorbid 
conditions on the individual’s risk for CACHES.  In addition, the researcher recommends 
further investigations into the influence of these demographic factors on medication 
adherence and subsequent stockpiling of unused medications. 
 
 
Geographical Location 
 
The CACHES study explored the relationship between geographical location 
(defined as Zip code for the purposes of this study) and the accumulation of unused 
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medications in the home.  Previous studies examined the relationship between urban/rural 
dwelling adults and the use of prescription medications (Carrie et al., 2006; Grymonpre 
& Hawranik, 2008).  These studies found location of residence did not have an effect on 
prescription drug purchase and use (Carrie et al., 2006; Grymonpre & Hawranik, 2008).  
However, studies propose adherence to prescribed medication regimens is more likely in 
patients who are both highly educated and earn a higher income (Rolnick et al., 2013).  
With nonadherence comes increased risk of unused medications in the home.  The 
CACHES study explores this relationship. 
 
In this pilot study CACHES of unused medications were found in 27 Davidson 
County Zip codes with half of CACHES distributed across just 6 Zip codes, including: 
37221 (4.9%), 37013 (5.5%), 37115 (7.9%), 37206 (8.5%), 37207 (9.1%), and 37211 
(14%).  According to the U.S. Census data (2011), 37211 had the highest percentage of 
males (50.7%) and second highest percentage of Caucasian/Non-Hispanics (67.9%) out 
of the 6 Zip codes.  Revisiting the earlier discussion, these two factors (Caucasian/Non-
Hispanic race and male gender) likely result in a higher rate of violent and/or traumatic 
deaths in this Zip code tract.  This in turn would increase the number of death 
investigation cases in this Zip code tract that fell under the jurisdiction of the Medical 
Examiner.  However it is important to note, due to the limited sample size, the CACHES 
data are insufficient to draw conclusions as to the relationship between geographical 
location and the stockpiling of unused medications.  Additional studies will be needed to 
clarify both the strength and direction of this relationship. 
 
 
Health Care Risk Factors 
 
In the CACHES model, the health care system plays a dual role – both as a 
contributor to risk and also as the victim of adverse events (increased health care 
utilization and wasted health care dollars) associated with the misuse and abuse of 
controlled substances, poisonings, and adverse drug events.  In the U.S., health care 
delivery is decentralized with health care consumers using multiple prescribers (primary 
care providers, specialists, dentists) and multiple dispensaries (pharmacies).  The ME 
data provide an opportunity to explore the relationship between the number of prescribers 
and dispensaries (health care system risk factors) with the formation of CACHES of 
unused medications in the home. 
 
 
 Number of prescribers. The ME pilot study data show a statistically significant 
relationship between the decedent’s use of multiple prescribers and unused medications 
in the home.  The existing literature supports this finding.  There are a number of prior 
studies identifying multiple prescribers as a risk factor for polypharmacy and subsequent 
nonadherence as well as adverse drug events (Barat et al., 2000; Boparai & Korc-
Grodzicki, 2011; Fulton & Allen, 2005; Hajjar et al., 2007; Junius-Walker et al., 2006; 
Prybys et al., 2002; Sorensen et al., 2005).  Both nonadherence and adverse drug events 
contribute to the presence of unused medications in the home.   
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 Number of dispensaries.  There are fewer studies examining the link between 
the number of dispensaries used as a risk for unused medications (Boparai & Korc-
Grodzicki, 2011; Torrible & Hogan, 1997; Werder & Preskorn, 2003).  However, the 
existing studies identify the use of multiple dispensaries as increasing the risk of the 
individual purchasing duplicate prescriptions as well as contraindicated medication 
regimens (Boparai & Korc-Grodzicki, 2011; Torrible & Hogan, 1997; Werder & 
Preskorn, 2003).  Other studies have identified the use of multiple dispensaries as a 
significant risk factor for the overprescribing, misuse and/or abuse of prescription opioids 
(Parente et al., 2004; Sullivan et al., 2010).   
 
In conclusion, the pilot study data support the CACHES model, which proposes a 
relationship between health care risk factors (use of multiple prescribers and 
dispensaries) and the accumulation of unused medications in the individual’s home. 
 
 
Limitations 
 
This pilot study was designed to describe the prevalence, size (number of bottles 
and pills), and types of unused medications stockpiled in the home.  The study used data 
originally collected by MLDIs in the course of death scene investigations in Davidson 
County, TN from January 1 - December 31, 2013.  This next section will discuss the 
limitations of this pilot study including 1) generalizability; 2) descriptive data; and 3) 
procedural limits on the original data collection. 
 
The generalizability of the study findings is limited due to the nature of the 
original data set.  As noted earlier, a comparison of the demographics of the ME data set 
to Davidson County population reveals the sampled ME data to be skewed towards 
Caucasian/Non-Hispanic males in the 44-64 year old age range.  The ME accepts 
jurisdiction in the case of violent, traumatic, and/or unexpected deaths in Davidson 
County.  The Department of Health Mortality statistics reveal that Caucasian/Non-
Hispanic men are at higher risk for suicide and traumatic (accidental) deaths than their 
female and non-Caucasian counterparts.  Furthermore, death rates secondary to natural 
causes are higher for African American men and women than Caucasian/Non-Hispanics 
across five leading cause of death categories.  Finally, older adults (≥65 years of age) are 
less likely to die from traumatic (homicide) deaths and more likely to die from natural 
causes (thus negating the need for the ME involvement) than their younger counterparts.   
 
The descriptive nature of this study did not allow for the determination of a causal 
relationship among the individual, geographical, and health care risk factors and 
CACHES.  Additional research is needed to clarify the nature of the relationships among 
the risk factors and the development of CACHES.  As noted earlier, there are several 
individual risk factors identified in the CACHES conceptual model that may serve as a 
protective mechanism rather than as a risk factor.  For example, while women are more 
likely to access and use prescription medications (thus possibly increasing the risk of 
unused medications in the home) previous research has shown them to be more adherent 
to prescribed medication regimens (thus decreasing the risk of unused medications).  
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Further research would help illuminate the possibility of co-linearity between certain risk 
factors.  For example, there is a question regarding the interplay between race, 
geographical location and socioeconomic status.  Prior studies examining adherence and 
race found if the researchers controlled for socioeconomic status, they uncovered the 
socioeconomic status to have a significant effect on adherence rather than race.  The 
CACHES conceptual model proposes there are multiple risk factors associated with the 
accumulation of unused medications in the home.  Determining the direction, power, and 
interplay between these risk factors will require a larger, more high-powered study or 
group of studies.   
 
Finally, the study prevalence rate likely underestimates the number of Davidson 
County households with unused medications in the home due to five limitations of the 
original data set including 1) legal restrictions on the MLDIs procedural search for and 
collection of medications during the death scene investigation; 2) legal restrictions set by 
the State and NAME guidelines requiring the MLDIs to determine ownership of the 
medications prior to collecting the medications; 3) potential diversion of the decedent’s 
medications by family members, roommates, friends, and/or others prior to law 
enforcement and the MDLI’s search of the scene; 4) missing dispensed dates negating a 
determination of whether the medication was currently in use versus unused; and, 5) an 
undercounting of older decedents due to the nature of their deaths (expected/natural). 
 
The MDLIs follow NAME and state guidelines restricting their search for 
medications to certain designated areas, including: a) common storage locations (bedside 
table, bathroom medicine cabinet, kitchen counters); b) those found in plain view of the 
decedent; and/or, c) those found on the decedent’s person.  In the community setting, 
individuals oftentimes store medication in multiple locations within the home.  As a 
result, standard MLDI search procedures might not uncover all of the decedent’s 
medications thereby contributing to an under sampling of the stockpile of unused 
medications in the home.  
 
Furthermore, MDLIs typically limit the collection and cataloging of medications 
to those clearly indicated as being dispensed to the decedent.  Identification of the end 
user can be difficult when prescription medications are found in unmarked containers.  
Furthermore, OTC medications typically do not have “dispensed to” information attached 
to the container.  The researcher was able to make a determination of “dispensed to” 
information for a portion of the CACHES OTC medication entries due to a subset of the 
decedents’ obtaining OTC medications through the Veteran’s Administration.  It is 
standard practice at the Veteran’s Administration to attach “dispensed to” information to 
both prescription and OTC medications.  However, overall the total number of unused 
OTCs in decedent’s homes was under sampled due to these medications being found in 
unmarked containers and/or a lack of “dispensed to” information.  
 
MLDIs’ Investigator Reports address law enforcement concerns about 
medications being removed from the decedent’s premises by family, roommates, or 
friends prior to law enforcement arrival on the scene.  This behavior most often occurs 
with controlled substances (opioids, benzodiazepines, stimulants, and barbituates).  This 
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diversion also could contribute to an under sampling of the decedent’s medications found 
at the death scene.  
 
Finally, out of the 1770 medication entries in the ME dataset, 21.1% lacked a 
“dispensed by” date.  This disallowed for the determination of whether the medications 
were in current use or unused at the time of death.  Therefore, the CACHES study 56% 
prevalence rate is likely an underestimation of the overall prevalence of unused 
medications. 
 
 
Practice and Policy Implications 
 
This research has practice and policy implications for the health care system 
(prescribers and dispensaries) as well as the individual health care consumer.  The 
CACHES framework highlights the need for a multi-interventional approach to reducing 
unused medications in the home.  The next section will discuss practice implications 
including the need to 1) change prescribing behaviors; 2) perform medication 
reconciliation at all points of patient contact in the health care continuum; 3) assess for 
adherence and barriers to adherence; and 4) educate patients on the importance of safe 
storage of currently-in-use medications and prompt disposal of unused medications to 
reduce the risk of diversion, accidental poisonings, and adverse drug events.  In addition, 
this section will address the policy implications of the CACHES study findings. 
 
 
Practice 
 
In the U.S. health care system, patients with comorbid conditions are likely being 
seen by more than one health care provider (Anderson & Horvath, 2004; Boparai & 
Korc-Grodzicki, 2011; Himmel et al., 1996; Lehnert et al., 2011; Mansur, Weiss, & 
Beloosesky, 2008; Prybys et al., 2002; Starfield et al., 2005).  This decentralized delivery 
of health care has the potential to contribute to polypharmacy or, at worst, duplicate 
prescriptions for the same medication or same medication class (Green et al., 2007; 
Linjakumpu et al., 2002; Mansur, Weiss, Hoffman, et al., 2008; New England Healthcare 
Institute, 2009; Prybys et al., 2002; Werder & Preskorn, 2003).  Polypharmacy 
contributes to poor adherence (Dunbar-Jacob & Mortimer-Stephens, 2001; Mansur, 
Weiss, Hoffman, et al., 2008; New England Healthcare Institute, 2009; Prybys et al., 
2002; Sorensen et al., 2005; Witticke et al., 2013) and adverse drug events (Boparai & 
Korc-Grodzicki, 2011; Prybys et al., 2002; Sorensen et al., 2004; Werder & Preskorn, 
2003).  Nonadherence results in poorly controlled comorbid conditions.  In response, a 
patient’s health care provider often makes changes to the patient’s medication regimen 
prior to his/her having used the entire 30 days of medication.  Adverse drug events have 
similar consequences.  The offending medication is discontinued and the patient placed 
on a different medication for the management of his/her chronic condition.  Both of these 
issues contribute to the accumulation of unused medications in the home.  Pharmacy 
returns data reflect these trends with common themes for returned unused medications 
being: provider changed prescription due to ineffectiveness, patient discontinued 
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prescription due to side effects, and/or provider changed prescription due to adverse drug 
event (Bolle et al., 2008; Braund, Gn, et al., 2009; Cameron, 1996; Coma et al., 2008; 
Garey et al., 2004; James et al., 2009; Langley et al., 2005).  
 
The CACHES study results highlight the relationship between a decentralized 
health care system – defined as the individual having multiple prescribers – and the 
accumulation of unused medications in the home.  Three prescriber behaviors aimed at 
reducing this risk for unused medications include: writing short scripts ((Herring et al., 
2008; Steiner et al., 1993), medication reconciliation, and collaborating with patients to 
increase adherence.   
 
 
Short scripts.  Writing short scripts for a new medication allows for the patient to 
have a trial period.  During this trial period, the patient and provider can determine the 
safety of the medication.  For example, does the patient experience any side effects that 
impact negatively on his/her quality of life?  Or is this medication going to cause an 
adverse drug event such as an allergic reaction or, at worst, anaphylaxis?  In each of these 
scenarios, there is a high chance the medication will be discontinued either by the patient 
or the prescriber.  The majority of side effects and adverse drug events occur within the 
first few days to weeks of a patient’s exposure to a medication.  As the pharmacy take-
back studies show, the remaining pills often are stockpiled in the home.   
 
Writing short scripts also allows for the provider to determine the efficacy of the 
medications and assess for patient adherence.  Best practices dictate the “start low and go 
slow” process of initiating a new medication.  Oftentimes, patients require a titration to 
effect on medications.  Therefore, it behooves the provider to give short scripts (14 days 
to 30 days) of the medication knowing there is a chance he/she will need to write another 
prescription for a higher dose, or different medication in the same class, in the near 
future. 
 
 
Medication reconciliation.  Prior research suggests regular medication reviews 
reduce polypharmacy and nonadherence (Sorensen et al., 2004).  This in turn reduces 
adverse drug events, hospitalizations, and even mortality (Mil et al., 2004; Sorensen et 
al., 2004; Wasserfallen et al., 2003; Werder & Preskorn, 2003).  Reviewing the patient’s 
current medications at each visit allows for the provider to determine if the patient is 
adherent to his/her medication regimen.  In addition, medication reconciliation allows the 
provider to determine what changes have been made by other providers involved in the 
patient’s care.  The CACHES model proposes coordination of care, in particular 
pharmacological interventions, could reduce the accumulation of unused medications in 
the patient’s home, as well as reduce the risk of adverse drug events.   
 
 
Adherence.  Improving adherence to prescribed medication regimens reduces the 
risk of stockpiles of unused medications in the home (Ruhoy & Daughton, 2008; 
Wasserfallen et al., 2003).  Estimates of nonadherence range from 50-60% (Choudhry et 
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al., 2009; Dunbar-Jacob & Mortimer-Stephens, 2001; Wasserfallen et al., 2003; Wilke et 
al., 2012), which results in a significant number of unused medications.  Over half of the 
CACHES study population had unused medications in the home.  These data emphasize 
the need for providers and patients to collaborate and improve patients’ medication 
adherence rates.  In addition to reducing the risk of adverse outcomes associated with 
unused medications in the home, increased adherence saves money by reducing wastage 
of health care dollars spent on medications and also reducing health care spending 
secondary to improved health outcomes. 
 
 
Policy Implications 
 
Currently there is a national discussion about how to provide the individual health 
care consumer access to a safe and reliable disposal site for his/her unused medications 
(Office of National Drug Control Policy, 2011).  One suggestion being considered is 
having pharmacies serve as disposal sites (Herring et al., 2008; Wasserfallen et al., 2003).  
This is the current practice in many non-U.S. countries (Great Britain, New Zealand, 
Spain, Germany, Kuwait, Iceland).  In the U.S., controlled substances, and the laws 
surrounding the disposal of these substances, complicates the disposal process.  The 2010 
Safe and Secure Drug Disposal Act sets the stage for this to change, but final regulatory 
guidelines have not yet been published by the DEA as to how this law will look in 
practice.  The DEA has put out several calls to the public requesting feedback on the 
2010 Safe and Secure Drug Disposal Act with the latest being in December, 2012 (Drug 
Enforcement Administration, 2012).  In the interim, the DEA has created a biannual 
“Drug Take Back” initiative coordinating with local law enforcement agencies to provide 
individual health care consumers the chance to bring their unused medications (including 
controlled substances) to specified locations for disposal.  However, these events are only 
a temporary measure and are not meant to be a sustained program for drug disposal.   
 
There are several issues with the proposed plan of having pharmacies be 
responsible for drug disposal.  First, there is the issue of the safety of the pharmacy staff.  
Second, there is the question of how returned medications will be monitored (to reduce 
possibility of black market diversion).  Third, who will pay for this disposal program?  
Should the costs be taken on by the pharmacies, the individual health care consumer, or 
the local, state, or federal government?  Some countries have proposed legislation 
requiring the pharmaceutical industry to assume the costs of disposal (Herring et al., 
2008).  Ultimately, final policy decisions surrounding the disposal of unused medications 
will require a coordinated effort from the DEA, FDA, National Board of Pharmacies, 
state Pharmacy Boards, the Pharmaceutical Industry, health care providers, and the 
individual health care consumer.   
 
 
Implications for Future Research 
 
The CACHES model proposes the accumulation of unused medications in the 
home setting are the result of a complex series of risk factors including a decentralized 
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health care system, restrictive state and regulatory guidelines, and individual 
characteristics of the health care consumer.  This pilot study explores the relationship 
between CACHES and the individual’s gender, race, age, number of comorbid 
conditions, geographical location, as well as the number of prescribers and dispensaries 
used by the individual.  The results of this study suggest advanced age, having a 
psychiatric comorbid condition, and the use of multiple prescribers and dispensaries 
increases risk for the individual having CACHES in the home.  However, additional 
research is needed to further investigate the effects of gender, race, comorbid conditions, 
and geographical location on CACHES.   
 
In addition, future studies are needed to explore the right-hand side of the 
CACHES model – adverse outcomes associated with unused medications in the home.  In 
particular, researchers should seek to clarify the relationship between CACHES and 
adverse outcomes for the individual (poisonings, diversion for misuse/abuse, adverse 
drug events, etc..), health care system (increased utilization of health care resources, 
wasted health care dollars), criminal justice system (victimization costs associated with 
drug crimes, incarceration costs related to prescription drug diversion/misuse/abuse), and 
ecosystem (APIs as pollutants).  
 
As the CACHES model proposes, the accumulation of unused medications in the 
home is a complex issue requiring the evaluation of the effectiveness of multiple 
interventions on reducing risk (upstream) as well as adverse outcomes (downstream).  
Suggested risk reduction interventions include 1) changing health care system practices 
(short scripts, medication reconciliation, assessing for adherence); 2) removing federal 
and state regulatory barriers (providing easy and safe access to drug disposal options); 
and 3) identifying high risk individuals (screening for polypharmacy, nonadherence, and 
poor health literacy, reducing risky behaviors such as improper storage, prescription 
stockpiling and sharing).   
 
Older adults (≥ 65 years of age) are a particular population of interest in future 
research on CACHES.  Older adults are at higher risk for having multiple comorbid 
conditions requiring pharmacological management.  In today’s health care system, this 
individual is managed by multiple providers in a variety of health care settings, which 
places them at higher risk for polypharmacy and ultimately contributes to nonadherence.  
As a result older adults are at risk for unused medications in the home.  Scientists and 
health care providers at the National Institutes of Health, the Gerontological Society of  
America, and other major Physician groups identify transitions of care (the point at which 
a patient is discharged from the hospital to skilled nursing facility, hospital to home, or 
skilled nursing facility to home) as contributing to the issue of polypharmacy, 
nonadherence, adverse drug events, and readmissions to acute care settings (Snow et al., 
2009).  Additional research is needed to identify how medication reconciliation, 
including the disposal of stockpiled unused medications, could reduce adverse outcomes 
including hospital readmissions and increased morbidity and mortality.   
 
Downstream interventions in need of evaluation include the development and 
implementation of environmentally friendly drug disposal mechanisms, as well as safe 
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and effective processes for the removal of APIs from the water supply.  Increasingly, 
communities are offering Drop Boxes at local police and fire department stations for 
community members to drop of their unused medications.  What is missing is an 
understanding of whether or not access to these types of disposal options has a significant 
impact on the accumulation of medications in the home.  Furthermore, there is the 
question as to what medications are being disposed of at these types of venues and what 
medications the individual might continue to store at home.  Previous studies have 
reported health care consumers hoarding unused antibiotics and pain medications with 
the intention of using them, as needed, at a later date (Bolle et al., 2008; Kotchen et al., 
2009).  A comparison of the types and frequencies of stockpiled medications in the home 
versus those brought to Drop Boxes would provide a better understanding of disposal 
patterns.  This information could then inform further interventions aimed improving 
disposal and reducing medications in the home.   
 
 
Summary 
 
The accumulation of unused medications by health care consumers results in 
Community-Based ACcumulation of Home mEdicationS (CACHES).  These stockpiles 
of unused medications place the individual, health care and justice systems, and 
ecosystem at risk for adverse outcomes.  Adverse outcomes for the individual include: the 
diversion of controlled substances by friends and family members, pediatric poisonings, 
and adverse drug events.  Health care costs associated with the treatment of adverse drug 
events, poisonings, and prescription drug abuse/misuse present an increasing financial 
burden for the health care system.  For the criminal justice system, adverse outcomes 
include the costs related to theft of prescription drugs and the incarceration of persons 
who committed crimes related to prescription drug abuse.  Finally, improper disposal of 
unused medications results in the pollution of local water supplies.  The CACHES model 
proposes health care systems risk factors (multiple prescribers, multiple providers, and 
prescribing practices), federal and state regulatory risk factors (The Controlled Substance 
Act 1970 and pharmacy rules), and individual risk factors (gender, race, age, comorbid 
conditions, polypharmacy, nonadherence, drug costs, drug hoarding, drug sharing, 
perceptions of medication safety, and geographic location) affect the individual’s risk for 
having CACHES in the home setting.   
 
This pilot study explores the relationship between individual risk factors (gender, 
race, age, comorbid conditions), geographical location, and health care risk factors 
(number of prescribers and number of dispensaries) and CACHES.  The researcher 
performed a secondary analysis of data extracted from charts created by the Medical 
Examiners and Medicolegal Death Scene Investigators of Forensic Medical, PLC in 
Nashville, Tennessee.  The study sample included 290 Davidson County residents whose 
deaths fell under the jurisdiction of the Medical Examiner’s office from January 1 
through December 31, 2011.  The study explored the prevalence, size, and composition 
of CACHES found in decedents’ homes.  In addition, a descriptive analysis was 
performed comparing the demographic data (gender, race, age, and comorbid conditions) 
of decedents with and decedents without CACHES in the home.  Additionally, the 
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geographic locations of CACHES were mapped.  Finally, the relationship between health 
care risk factors (number of prescribers, number of dispensaries) and the presence or 
absence of CACHES was explored.   
 
There was no statistical difference in the gender, race, or age of decedents with 
medications (used and unused) and decedents without medications in the home.  In 
contrast to the Davidson County general population, the CACHES study sample was 
majority male, Caucasian/Non-Hispanic, and older.  The prevalence rate of CACHES 
was 56%.  More than half of decedents with CACHES had a mean of 38.9 (SD ± 43.7) 
unused pills and ≥4 bottles of unused medications.  Sixty percent of the unused 
medications came from two major classes – those affecting the central nervous system 
and the cardiovascular system.  The decedents with CACHES were significantly older, 
had a higher likelihood of having a psychiatric diagnosis, and used more prescribers and 
dispensaries than those without CACHES in the home.  The two groups did not 
statistically differ with regards to gender, race, or comorbid conditions.  
 
The generalizability of the study findings is limited due to the nature of the 
original data set.  The ME accepted jurisdiction for violent, traumatic, and/or unexpected 
deaths.  As a result, the ME data skewed towards Caucasian/Non-Hispanic males in the 
44-64 year old age range.  Furthermore, statistical determination of a causal relationship 
among the individual, geographical, and health care risk factors and CACHES could not 
be performed.  The calculated prevalence rate is a likely underestimation secondary to the  
legal restrictions regarding the search and seizure of medications from in-home death 
scene investigations.  Furthermore, older adult decedents were under represented in the 
study sample due to their increased risk of having a death ruled as natural and/or 
expected.  This under sampling of older adult decedents likely decreased the study 
prevalence rate.  In addition, there was an under representation of controlled substances 
in the study sample due to diversion of these medications by family and friends prior to 
law enforcement arrival on scene.  Finally, approximately 20% of the medication data 
were missing “dispensed by” dates, thereby necessitating the exclusion of these data from 
the final analyses.   
 
The CACHES conceptual model identifies individual, health care system, and 
federal and state regulatory risk factors associated with the accumulation of unused 
medications in the home.  Additional research is needed to determine the relationship 
between gender, race, comorbid conditions and CACHES.  Furthermore, future research 
must focus on establishing a causal relationship between CACHES and adverse outcomes 
for the individual, health and criminal justice systems, and ecosystem.  Proposed 
interventions for the reduction of CACHES include: changes to prescribing practices, 
assessing individuals for risk of CACHES, improving transitions of care across different 
health care settings, and expanding the individual health care consumer’s access to easy 
and safe medication disposal options.   
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